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1  Introduction 
1.1 Bone remodeling 
1.1.1 Bone structure and homeostasis  
Bone is a very dynamic and complex tissue that is constantly being remodeled by specialized 
cells. This coordinated process is responsible for renewing the skeleton and maintaining the 
bone structure [1]. Bone formation and resorption are in essence mediated by two cell 
lineages: the bone-forming osteoblasts and the bone-resorbing osteoclasts. In physiological 
bone remodeling, bone formation and bone resorption are closely coupled processes (Fig. 1) 
[2].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 [3] 
 
 
 
Both bone cell types derive from precursor cells, which develop at bone surfaces. 
Osteoblasts originate from multipotent, mesenchymal stem cells and require the control of 
growth factors and cytokines, such as bone morphogenetic proteins and Wnt signaling, which 
stimulate the transcription of osteoblast-specific proteins, such as runt-related protein-2 
(RUNX-2), osterix, osteopontin, osteocalcin (OCN) or alkaline phosphatase (ALP) [4]. 
Osteoclasts develop from macrophage/monocyte lineage precursor cells to multinucleated 
Figure 1. Bone remodeling cycle. The picture displays a microcrack that damages canaliculi and 
leads to apoptosis of osteocytes. Simultaneously, local factors that attract cells from blood and marrow 
to the remodeling compartment are secreted by lining cells and osteocytes. In this remodeling 
compartment osteoclasts degrade matrix. The resorption lacuna is filled by depositing new lamellar 
bone by osteoblasts. Osteoblasts that are trapped within the matrix are referred to as osteocytes, 
while osteoblasts that become dormant at the bone surface are referred to as lining cells [3]. 
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giant cells with a characteristic bone-resorbing organelle with finger-shaped projections called 
the ruffled border (Fig. 2) [4]. Their development includes proliferation, differentiation, fusion, 
and activation and requires the presence of macrophage colony-stimulating factor (M-CSF) 
as well as activation of receptor activator of nuclear factor-κB (RANK) by its ligand RANK-
ligand (RANKL). Further important factors are interleukin (IL)-1, IL-4, IL-6, IL-7, IL-11, IL-17, 
tumor necrosis factor (TNF), transforming growth factor-β, and several hormones [1].  
 
 
 
 
 
 
 
 
 
 
 
 
 
   [5] 
 
 
 
 
 
 
1.1.2 Bone formation and Wnt signaling pathway 
Differentiated osteoblasts form bone by producing a collagenous matrix and furthermore they 
are essential for its mineralization. This is meaningful for the bone density, which increases 
by displacing water due to the mineralization process. The bone volume is determined by the 
matrix synthesis, but not by the mineralization. Moreover osteoblasts are important for the 
Figure 2. Bifunctional role of the Wnt signaling pathway in the regulation of osteoblast and 
osteoclast differentiation. Wnt signaling supports the mesenchymal stem cells developing into 
osteoblasts. The Wnt antagonist Dkk-1 blocks Wnt signaling by binding to the Wnt receptor complex 
on the surface of the osteoblast lineage cells, leading to arrest of osteoblast proliferation and 
differentiation. Osteoblast precursors enhance bone resorption by intensifying RANKL-induced 
osteoclastogenesis. Dkk-1 blockade permits osteoblast differentiation. Activation of the Wnt signaling 
pathway in the mature osteoblasts increases OPG, leading to decreased RANKL production which 
leads to reduced osteoclastogenesis, resulting in inhibition of bone resorption. Dkk-1 – dickkopf-1, 
OPG – osteoprotegerin, RANKL – receptor activator of nuclear factor κB ligand, TNF-α – tumor 
necrosis factor-α [5]. 
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regulation of calcium and phosphate concentrations [4] and produce cytokines, such as 
RANKL, which activates osteoclastogenesis, and osteoprotegerin (OPG), a soluble decoy 
receptor for RANKL, which inhibits osteoclastic differentiation [2]. Further important functions 
of osteoblastic cells are the maintenance of hematopoietic stem cell niches and homing as 
well as their ability to act as non-professional antigen-presenting cells in inflammatory 
conditions [6]. Moreover, by producing OCN, osteoblasts regulate energy metabolism and 
male fertility [7,8].    
 
 One pathway that is important for the development of osteoblasts is the Wnt 
pathway [9]. The Wnt signaling pathway is one of the best studied signaling pathways. The 
first member of the Wnt molecules was found by Roel Nusse and Harold Varmus and was 
named integration-1 (int-1) because it is activated during the induction of mammary gland 
tumors in mice by a tumor virus (Mouse Mammary Tumour Virus, MMTV). In 1973 already, 
the 1995 Nobel laureate Christiane Nüsslein-Volhard together with Eric F. Wieschaus und 
Edward B. Lewis discovered a new gene responsible for wing development in Drosophila 
melanogaster and called it Wingless (Wg). Later they recognized that both genes were the 
same and established the term Wnt (Wingless-type MMTV Integration Site Family) [10].  
  
 Wnts are secreted glycoproteins (39 – 46 kDa) that have been identified in several 
different organisms. They exhibit sequence homology to Drosophila wingless and the murine 
int-1 proto-oncogene. Nineteen human Wnt genes have been identified so far that are 
involved in morphogenesis, embryogenesis, or cellular differentiation, and are important 
regulators of bone biology [11]. Wnts can act via several signaling cascades that are normally 
divided into the canonical or the non-canonical pathway. Typically, Wnt signaling is mediated 
by the Wnt/β-catenin-dependent pathway, which is in general referred to as canonical 
pathway. This cascade seems to be important for the maintenance of bone mass. Binding of 
canonical Wnt ligands such as Wnt-1, Wnt-3, Wnt-3a, Wnt-8, or Wnt-10b to the receptor 
Frizzled (FZD)-5 and the co-receptor low-density lipoprotein receptor (LRP)-5/6 leads to 
activation of dishevelled proteins, which inhibit a multiprotein complex consisting of casein 
kinase 1, glycogen synthase kinase 3β, and scaffolding proteins like axin and adenomatous 
polyposis coli. Consequently, β-catenin, which is ubiquitinylated and degraded in the absence 
of Wnt ligands, is stabilized and translocates into the nucleus to affect gene expression alone 
or in combination with T cell factor/lymphoid enhancer factor 1. Non-canonical Wnts like Wnt-
4, Wnt-5a, or Wnt-11, activate other pathways such as the Wnt/Ca2+ pathway, which 
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increases intracellular calcium levels and activates protein kinase C or the Wnt/planar polarity 
pathway, which modulates cytoskeletal organization and gene expression [6,11,12]. 
 
  Wnt signaling is regulated by several secreted inhibitor proteins such as members of 
the dickkopf (Dkk) and secreted frizzled-related protein (sFRP) family, Wnt inhibitory factor 
(WIF)-1, and sclerostin (Sost). They bind directly to the Wnt ligands and FZDs (sFRPs, WIF-
1) or interfere with the LRP-5/6 co-receptors (Dkk, Sost) [11,13]. Hence, those members of 
the Dkk family as well as Sost only inhibit canonical Wnt signaling whereas members of the 
sFRP family can block both, canonical and non-canonical Wnt signaling. Moreover, 
glucocorticoids (GC) increase sFRP-1 and thereby inhibit osteogenesis [14–16]. Dkk-1 was 
identified by the group of C. Niehrs, who showed that it blocks cells from receiving the Wnt 
signal [17,18]. Further functions of Dkk-1 were identified using Dkk-1 knockout animals. 
Homozygous Dkk-1 knockout mice show defects in head formation resulting in anterior 
truncations and death at birth [19,20]. In contrast, heterozygous Dkk-1 (Dkk-1+/-) mice are 
viable, allowing for the use of these mice for the analysis of the physiological role of Dkk-1 in 
bone. The observed results showed that a reduction in Dkk-1 increased trabecular and 
cortical bone mass in mice [19,21,22]. Experiments using mice overexpressing Dkk-1 
demonstrated that enhanced levels of Dkk-1 in the circulation or within bone were able to 
suppress bone formation and resorption leading to reduced bone mass in adult mice [19]. 
Further evidence on the role of Dkk-1 emerged from different disease models such as 
multiple myeloma or arthritis. Therein Dkk-1 expression by malignant plasma cells was 
directly correlated with increased skeletal disease concluding that Dkk-1 inhibits osteoblast 
maturation and bone formation in patients suffering from multiple myelomas [11,23]. Likewise, 
Dkk-1 has been shown to be increased by inflammatory stimuli, enforcing inhibition of bone 
formation near inflammatory areas (Fig. 3). Since the natural source of Dkk-1 was not known, 
Gregory et al. studied this issue and showed that Dkk-1 is produced by osteoblast lineage 
cells such as MG63, SaOS-2 osteosarcoma cells, and osteocytes [24].  
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 [25] 
 
 
 
 
Regulation by glucocorticoids (GC) 
GC belong to the group of steroid hormones and are further described in this thesis under 1.3 
(p.12). Besides regulating several developmental, immunological, neurological, and metabolic 
processes, they are critical for bone remodeling [26]. Whereas physiological amounts of 
endogenous GC are essential for proper osteoblast differentiation due to activation of crucial 
osteoblast pathways, such as the canonical Wnt pathway [27–29], excess of GC enhance 
adipogenesis by shifting the osteoblast-adipocyte balance toward adipocytes (Fig. 4, left 
part). Thereby osteoblast differentiation and function (Fig. 4, mid bottom part) is inhibited 
while apoptosis of osteoblasts and osteocytes is enhanced (Fig. 4, mid and right part) [26]. 
Moreover, investigations from our lab using human osteoblasts derived from bone marrow 
stromal cells (BMSC) showed that the presence of physiological amounts of GC is necessary 
for efficient in vitro differentiation [28,30]. As mentioned above, GC were shown to be critical 
regulators of Dkk-1 expression. Dexamethasone (DEX) enhances Dkk-1 expression in 
primary cultured human osteoblasts and by blocking Dkk-1 with RNAi, GC-induced bone loss 
in mice can be prevented [14], suggesting an important role of Dkk-1 in the suppression of 
Figure 3. Dkk-1 is both catabolic and anti-anabolic in bone. TNF-α-induced enhanced Dkk-1 
production inhibits MSC-derived osteoblastogenesis and reduces OPG levels, leading to reduced 
bone accretion. Furthermore, Dkk-1 increases levels of RANKL and the enhanced RANKL/OPG ratio 
stimulates osteoclast activity, resulting in bone resorption. Dkk-1 – dickkopf-1, MSC – mesenchymal 
stem cell, OPG – osteoprotegerin, RANK(L) – receptor activator of nuclear factor κB (ligand), TNF-α – 
tumor necrosis factor-α [25]. 
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osteoblast functions by GC [15,31]. In addition, it was demonstrated that whereas Dkk-1 
negatively regulates bone formation by inhibiting Wnt signaling, it restricts OPG expression 
leading to a shift in the RANKL/OPG ratio towards bone resorption. Therefore Dkk-1 also 
induces bone resorption (Fig. 3) [25,32].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Cellular effects and molecular pathways employed by GC in the homeostasis of bone. 
GC (for example cortisol) increase the expression of adipogenic and osteogenic transcription factors. 
The left side shows that long-term exposure leads to an increase of adipogenesis (orange). The 
osteoblastic transcription factors RUNX-2 and Wnt are suppressed by the GC-mediated arrest of 
various signaling pathways and attenuate the differentiation of osteoblasts. Blockade of osteoblast 
differentiation leads to lower production of extracellular bone matrix proteins (collagen type I, 
osteocalcin). Stimulation of Dmp1 and Phex, both mineralization inhibitors, impairs matrix 
mineralization (blue). GC enhance osteoblast and osteocyte apoptosis by increasing caspase-
mediated up-regulation of the Bim and Fas/FasL systems. GC-mediated apoptosis is prevented by  
osteoprotective drugs such as PTH analogues and bisphosphonates (green). GC directly extend 
osteoclast survival via caspase-3 while reducing osteoclast activity through blocking M-CSF-mediated 
pathways. Moreover, number and activity of osteoclasts are modulated by increasing the RANKL/OPG 
ratio while inhibiting the pro-osteoclastic cytokines IL-1, IL-6, and TNF-α. Denosumab, an antibody 
against human RANKL, can prevent GC-induced enhanced osteoclastogenesis (purple). BMP - bone 
morphogenetic protein, Dkk-1- dickkopf-1, M-CSF - macrophage-colony stimulating factor, OPG – 
osteoprotegerin, RANKL – receptor activator of nuclear factor κB ligand, SRC - src proto-oncogene, 
sFRP-1 - secreted frizzled-related protein-1 [26]. 
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1.1.3 Bone resorption and RANKL/OPG balance 
The resorption of the calcified bone matrix is mediated by bone resorbing osteoclasts. With 
their ruffled border, which is surrounded by the sealing zone, containing actin-like filaments, 
they attach to the bone surface. Thereby the formation of a microenvironment needed for the 
resorptive apparatus is enabled. The resorption process progresses as an acidic environment 
is created by an ATP-driven proton pump in the ruffled border membrane leading to 
degradation of matrix mineral components (collagen). Additionally osteoclasts secrete matrix 
metalloproteinases and cathepsins K, B, and L [4]. 
 
The balanced processes of bone resorption coupled with bone formation 
continuously remodel and modify the skeleton [33]. One powerful modulator of osteoclast 
formation and activity, thus bone resorption, is the RANKL/OPG cytokine network [34,35]. 
The discovery of the two proteins goes back to the late 1990s. Simonet et al. demonstrated 
OPG since mice overexpressing this protein developed an osteopetrotic phenotype [36]. 
Furthermore they found that OPG, which is produced by pre-osteoblasts, is able to inhibit the 
development and activation of osteoclasts. The protein belongs to the tumor necrosis factor 
(TNF) receptor superfamily and is expressed on many tissues such as heart, liver, intestine, 
spinal cord, and bone [6,36]. RANKL, which is also named TNF-related activation-induced 
cytokine (TRANCE), osteoclast differentiating factor (ODF), OPG ligand (OPGL), or TNF 
superfamily member 11 (TNFSF11), was discovered after OPG. Kartsogiannis et al. detected 
its expression on a variety of tissues, including bone, kidney, brain, heart, intestine, liver, 
mammary tissue, spleen, and testis [6,37]. Therefore it has many different functions but the 
most important one is the regulation of bone remodeling as detected in RANKL-knockout 
mice, which display a severe osteopetrotic phenotype because of the decreased number of 
osteoclasts [6,38]. Similar to OPG, RANKL is a member of the TNF superfamily and is 
expressed by pre-osteoblasts and activated T cells [6,39]. The receptor for RANKL is RANK, 
which is expressed in almost all tissues that express RANKL too, but mostly on osteoclasts 
and their precursors. Similar to OPG, RANK belongs to the TNF receptor superfamily. The 
phenotype of RANK-knockout mice is similar to that of RANKL-knockout mice [6,40]. When 
RANKL binds to RANK, a signaling cascade is initiated, which in the end leads to activation of 
transcription factors such as nuclear factor κB (NF-κB), nuclear factor of activated T cells, 
activator-protein 1 or cascades of mitogen-activated protein kinases such as p38 stress 
kinase, c-Jun N-terminal kinase or extracellular signal regulated kinase [6,41,42].  
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Regulation by GC 
Besides the effects on the osteoblastic lineage, GC also exert direct and indirect effects on 
osteoclasts. For instance, it has been shown that the expression of pro-osteoclastic cytokines 
such as IL-1 and IL-6 in osteoblasts and stromal cells is inhibited after GC exposure. In spite 
of that, one important key mechanism of GC-induced bone loss seems to be the increase of 
the RANKL/OPG ratio (Fig. 4, mid upper part) [26,43]. Recent findings of our lab showed that 
pharmacological inhibition of RANKL by denosumab, an anti-RANKL antibody, maintained 
bone mass and bone strength and suppressed bone resorption during a 4-week course of GC 
treatment [34,43]. This indicates that the RANKL/OPG pathway is crucial for the induction of 
GC-induced bone loss [44]. Furthermore the direct effects of GC on osteoclasts in vitro are 
not clearly understood whereas the fact that GC prolong osteoclast survival by inhibiting 
caspase 3-dependent apoptosis was recently revealed using in vivo studies (Fig. 4, mid 
upper part) [26,45,46]. Moreover, by interfering with ruffled border formation, osteoclast 
activity was reduced [46].  
 
1.2 Rheumatoid arthritis 
The highly prevalent chronic inflammatory disease rheumatoid arthritis (RA) affects about 1% 
of the Western population. In Germany the number of cases has been estimated to be 
800,000 patients [47]. Although RA can occur at any age, the peak incidence is between 40 
and 60 years of age [48]. The main targets of this autoimmune disorder are the synovial 
membrane, cartilage and adjacent bone resulting in impaired joint function and a significant 
loss in the quality of life owing to pain and reduced mobility [47]. Even though there is an 
increasing understanding of the mechanisms underlying RA, it still remains a challenge to 
combine all the various aspects to comprehend the disease pathophysiology in its totality [6]. 
However, efforts from the past years have shown that there are different molecular and 
cellular mechanisms, as well as genetic elements and environmental factors that contribute to 
the pathogenesis of RA. Furthermore many different auto-antibodies are detectable in the 
sera of RA patients including the rheumatoid factor or auto-antibodies against citrullinated 
filaggrin [6,49,50]. Moreover, it was found that RA is primarily a Th1-mediated disease, 
meaning that TNF-α, IL-1, IL-6, and IFN-γ are the main mediators of disease. Additionally, IL-
17 and IL-23 have been identified as critical regulators of RA [6,51]. Besides the persistent 
inflammation leading to cartilage breakdown and disability, another central feature of RA is 
bone erosion, which is associated with disease severity and poor functional outcome resulting 
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from excessive local bone resorption and ineffective bone formation. Bone erosion in arthritis 
is triggered by synovitis, characterized by the production of pro-inflammatory cytokines by 
macrophages including RANKL [6], which induce the differentiation of osteoclasts and inhibit 
bone formation. Figure 5 from Schett & Gravallese shows the evolution of bone erosion in the 
course of RA [52].  
 
 A common treatment strategy for RA is the use of GC, because of the pleiotropic 
impact of the glucocorticoid receptor (GR) on several signaling cascades [53].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.3 Glucocorticoids and glucocorticoid receptor 
In the body GC are synthesized from cholesterol inside of the adrenal cortex. The synthesis is 
closely regulated by the hypothalamic-pituitary-adrenal axis and is based on the balance of 
corticotropin-releasing hormone (CRH), secreted by the hypothalamus and 
adrenocorticotropin, secreted by the anterior pituitary gland. Adrenocorticotropin stimulates 
the adrenal cortex to synthesize and secrete cortisol [53,54]. The daily rate of cortisol 
secretion follows a circadian rhythm and amounts 10 – 20 mg in healthy individuals. The main 
physiological functions of GC are to regulate the carbohydrate, protein, and fat metabolism. 
Furthermore they protect glucose-dependent tissues like the brain and the heart during 
starvation via stimulation of gluconeogenesis and glycogen synthesis [55]. Additionally, all 
Figure 5. Evolution of bone erosion in the course of RA. Plasma cells produce anti-citrullinated 
protein antibodies (ACPA) which stimulate osteoclast differentiation and therewith initiate bone loss. 
Cytokine production induced by synovitis leads to RANKL expression and thus promotes 
osteoclastogenesis leading to enhanced bone erosion. On the right, the established form of RA is 
shown, which is characterized by large bone erosion filled with inflammatory cells [52]. 
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cell types found in bone tissue are influenced by GC. Whereas physiological levels are 
required for proper bone development, pathological levels can suppress bone formation and 
stimulate bone resorption [56]. GC also regulate the activity of peripheral leukocytes by 
suppressing the cytokine and chemokine production and changing the life span of immune 
cells, thereby modulating immune responses and acting immunosuppressive [55]. The latter 
effect coupled with their great potency in suppressing inflammation is the main reason for the 
application of GC in clinical practice. Despite their efficiency, the use of GC is limited by 
several side effects including the induction of osteoporosis (GC-induced osteoporosis, GIO), 
which is caused by the loss of bone mass [26,55]. Furthermore their negative effects 
comprise disorders of the glucose (diabetes mellitus) and lipid metabolism, hypertension, 
muscle wasting, impaired wound healing and skin atrophy, increase susceptibility to 
infections, cataract, peptic ulcers, behavioural alterations and other dysfunctions [54,57]. One 
of the most common side effects of long-term and high dose GC treatment is the Cushing 
syndrome, which can also occur due to the excessive production of endogenous GC after 
enhanced secretion of adrenocorticotropic hormone [58]. Patients suffering from Cushing’s 
disease display several symptoms including excessive weight gain resulting in central 
obesity, growth of fat pads along the collar bone and the characteristic “moon face”, 
osteoporosis, thinning of the skin and purple or red “striae” (resulting from the massive weight 
gain), hypertension, diabetes mellitus, immune suppression, baldness, and many more [58].  
 
Because of their lipophilic nature GC diffuse into cells and exert their effects via the 
GR, which is a member of the nuclear receptor superfamily and its subfamily 3C (NR3C1) 
[59,60]. The GR is expressed in almost every cell in the body and resides in the cytoplasm in 
the absence of the ligand [61,62]. GC can mediate their effects via different mechanisms to 
either transactivate or transrepress genes (Fig. 6). After ligand binding and a conformational 
change of the GR the newly formed complex translocates into the nucleus and activates 
genes via binding to GC-responsive elements (GRE) [26,62]. While activation of many genes 
involved in metabolic processes are mediated through binding of GR dimers to GRE, most of 
the immunosuppressive effects are traditionally thought to be mediated through 
transrepression by GR monomers (e.g. the repression of NF-κB or AP-1) [62–65]. 
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[66] 
 
 
 
 
 
1.4 Glucocorticoid-induced osteoporosis 
Osteoporosis is a chronic disease that is characterized by a systemic impairment of bone 
mass, strength, and microarchitecture. Fractures occur in 30 - 50% of osteoporosis patients 
receiving GC therapy. Mostly, sites predominantly made of cancellous bone such as spine, 
hip, proximal humerus, and wrist are affected by fractures, which result in chronic pain, loss 
of autonomy, and increased mortality [67]. While steroid-induced osteoporosis is the most 
common form of secondary osteoporosis, it is also one of the most frequent and far-reaching 
side effects of anti-rheumatic therapy. The strongest loss of bone density occurs during the 
first year of GC treatment [68,69]. Thereafter, the loss of bone mineral density becomes 
slower (3% loss yearly). However, the fracture risk rises up to 75% within the first three 
months after treatment onset [70]. Today, it is clear that GC affect all three major bone cell 
Figure 6. Molecular mechanisms of glucocorticoid (GC) action. GC exert their effects either via 
binding to the GR homodimer, which then binds directly to GRE in the promoter region of target genes 
(transactivation), or by binding GR monomers, which interfere with transcription factors that are 
required for the induction of pro-inflammatory cytokines (transrepression). While the adverse effects of 
GC on metabolism are thought to be provoked by transactivation mechanisms, transrepression is 
proposed to mediate the positive anti-inflammatory effects of GC.  GC – glucocorticoids, GR – 
glucocorticoid receptor, GRE - glucocorticoid responsive elements [66]. 
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types resulting in a net loss of bone mass (Fig. 7). A central feature in the pathogenesis of 
GIO is the suppression of bone formation, caused by the decreased number and function of 
osteoblasts after GC treatment. However, physiological concentrations of GC are inevitable 
for the differentiation of osteoblasts from mesenchymal stromal cells [26]. GC also inhibit 
osteoblast differentiation via enhancing Dkk-1 expression and inactivating β-catenin and the 
Wnt signaling pathway. Whereas the differentiation towards osteoblasts is impaired by GC, 
the differentiation towards adipocytes is enhanced. Additionally GC suppress mature 
osteoblastic cell function by decreasing the synthesis of type I collagen, the major component 
of the bone extracellular matrix. Furthermore GC affect osteocyte function and increase its 
apoptosis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
While decreasing osteoblast function, GC increase osteoclast formation by inducing RANKL 
and M-CSF and therewith support bone resorption. Thus, GC have damaging effects on 
Figure 7. Direct effects of glucocorticoids (GC) on bone cells. This scheme shows the adverse 
skeletal changes resulting from an excess of GC leading to osteoporosis and osteonecrosis. Apoptotic 
osteoblasts and osteocytes are shown as brown, condensed cells. They disrupt the osteocyte-lacunar-
canalicular network and lead to cell death and impaired bone quality [70]. 
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osteoblasts and osteocytes whereas they extend osteoclastic lifespan [69,71,72]. In addition 
to the direct effects of GC on bone cells they also have indirect extraskeletal effects on bone 
metabolism as they influence the calcium homeostasis by inhibiting its absorption from the 
gastrointestinal tract. Furthermore the steroids decrease the expression of calcium channels 
in the duodenum and increase the urinary excretion by inducing resistance to vitamin D [70].  
 
The first step in the therapy of GIO is adequate calcium (1,200 mg/day) and vitamin 
D (800 – 2,000 U/day) supplementation. Bisphosphonate treatment represents the common 
first-line therapy, however, there are controversies on the doses and duration of the therapy. 
The most commonly used bisphosphonates are alendronate, zoledronic acid, and 
risedronate. Also approved for the treatment of GIO is teriparatide, a recombinant human 
parathyroid hormone (1-34) [70]. An alternative to bisphosphonates and teriparatide is 
denosumab, a humanized monoclonal antibody to RANKL. Even though it is used for the 
treatment of postmenopausal osteoporosis, the Food and Drug Administration (FDA) did not 
yet approve denosumab for the treatment of GIO [70]. However, a recent animal study 
showed that denosumab prevented the prednisolone-induced bone loss in human RANKL-
knock-in mice [73] and a clinical study demonstrated its efficacy in preventing bone loss in 
GIO patients [74].  
    
1.5 The selective glucocorticoid receptor agonist (SEGRA) compound A 
Because of the several side effects of GC there is still a need for new agents that can be 
used for the treatment of inflammatory diseases. Therefore current research has focused on 
the development of novel selective GR agonists (SEGRAs), which still have anti-inflammatory 
properties but exhibit reduced side effects compared to conventional GC. These so called 
dissociating GC are supposed to act solely via transrepression mechanisms by GR 
monomers, whereas the negative effects of classical GC are mostly mediated via 
transactivation by GR dimers [30,57,75]. Several selective GR modulators, such as AL-438, 
ZK216348, LGD5552 or compound A, have been developed and were analyzed for their anti-
inflammatory effects [62]. Compound A (CpdA) or 2-(4-acetoxyphenyl)-2-chloro-N-methyl-
ethylammonium chloride (Fig. 8) is one of the best studied selective GR modulators. 
Chemically it is a non-steroidal stable analogue of the hydroxy phenyl aziridine precursor, 
which was found in the Namibian shrub Salsola tuberculatiformis Botschantzev.  
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Compared to classical GC, CpdA fails to transactivate GRE-driven genes whereas it 
interferes with the capacity of NF-κB or AP-1 to bind DNA and activate target genes, similar 
to conventional GC. The GR monomer-favouring potential of CpdA is in contrast to the GR 
dimer-favouring potential of typical GC, such as dexamethasone (DEX), and could be the 
reason for the dissociating character of CpdA [57,62,76,77].  
 
The potent anti-inflammatory potential of CpdA was already demonstrated in a few 
studies using various inflammatory mouse models such as arthritis, neuritis, and multiple 
sclerosis [30,76,78,79]. Additionally, a rat model of autoimmune neuritis was used to show 
the inflammation-reducing effects of CpdA [80]. Despite its potent anti-inflammatory actions, 
side effects of CpdA were reported including the induction of apoptosis in vitro and in vivo. 
Nevertheless, previous studies on bone cells propose a bone-sparing potential of CpdA as it 
did not increase the RANKL/OPG ratio in bone marrow stromal cells or the numbers of 
osteoclasts in vitro while conventional GC induced both, the RANKL/OPG ratio and the 
number of osteoclasts [30]. Furthermore CpdA did not affect the production of IL-11 or 
osteoblast differentiation, whereas DEX was shown to inhibit osteoblast differentiation 
through suppressing IL-11 [75].  
Figure 8. Chemical structure of compound A [57]. 
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2  Objective 
GC are the gold standard in the basic treatment of inflammatory diseases such as RA. 
However, the use of these effective drugs is limited by adverse effects on bone mass and 
strength, leading to an increased rate of osteoporotic fractures. By increasing osteoblast and 
osteocyte apoptosis as well as by stimulating osteoclastogenesis through the RANKL/OPG 
network GC decrease bone mass. The recent observations that GC-induced bone loss is 
prevented by blocking RANKL with a monoclonal antibody (denosumab) or Dkk-1, an inhibitor 
of osteoblast differentiation, using RNAi, demonstrate the importance of these pathways in 
the pathogenesis of GIO. To circumvent side effects caused by GC, SEGRAs were 
developed that display an improved risk/benefit profile. In particular, the ability of the novel 
SEGRA, CpdA, to suppress inflammation while exerting fewer side effects was tested in 
previous studies. While CpdA displayed potent anti-inflammatory effects in vitro and in vivo 
and revealed a superior risk/benefit profile regarding glucose metabolism, its effects on the 
skeleton remain unknown. Thus, the aim of this study was to determine the effects of CpdA 
on the skeleton and evaluate its potential as novel anti-inflammatory agent.  
 
The central hypothesis of this thesis is that the selective GR modulator CpdA 
suppresses inflammation and prevents skeletal side effects through different GR-mediated 
mechanisms in bone cells. To test this hypothesis, the following aims were defined:  
 
1. to determine the influence of SEGRAs on bone metabolism  
2. to assess the in vivo efficacy and side effect profile of SEGRAs in different mouse 
models of arthritis 
3. to investigate which signaling pathways are affected by SEGRAs in immune and bone 
cells (RANKL/OPG, Wnt pathway). 
 
Further investigations concerning the concept and mode of action of SEGRAs could 
help to improve and optimize the treatment of inflammatory diseases using new developed 
agents with great therapeutic potential. 
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3  Materials & Methods 
3.1 Materials 
3.1.1 Reagents 
Substance Supplier, city, country 
Acetic acid (100%) Merck, Darmstadt, Germany 
Acetone Merck, Darmstadt, Germany 
Acrylamid (Bisacrylamid)  Carl Roth, Karlsruhe, Germany 
Agarose ultra pure Serva, Heidelberg, Germany 
3-Aminopropyl-triethoxysilane Sigma-Aldrich, München, Germany 
Ammonium persulfate  Serva, Heidelberg, Germany 
Antibiotics/antimycotics PAA, Cölbe, Germany 
Antibodies 
   anti-human DKK-1 (H-120)  
   anti-human/murine GAPDH            
   (5G4 MAb 6C5)  
   anti-murine caspase-3 (#9662) 
   anti-murine caspase-7 (#9492) 
   anti-murine CD3e (#17-0031-82) 
   anti-murine Dkk-1 (MAB1765) 
   anti-murine IgG (HAF007)  
   anti-murine IgG1 (A90-205P) 
   anti-murine IgG2a (A90-207P) 
   anti-murine RANKL (PE-labeled      
   12-5952-81) 
   Rabbit IgG Horseradish per- 
   oxidaseconjugated antibody 
   (HAF008) 
   Rat IgG Horseradish per- 
   oxidaseconjugated antibody  
   (HAF005)  
 
Santa Cruz, Heidelberg, Germany  
HyTest Ltd, Turku, Finland 
 
Cell signalling, Frankfurt/Main, Germany 
Cell signalling, Frankfurt/Main, Germany 
eBioscience, Frankfurt/Main, Germany 
R&D Systems, Wiesbaden-Nordenstadt, Germany 
R&D Systems, Wiesbaden-Nordenstadt, Germany 
Bethyl, Biomol GmbH, Hamburg, Germany 
Bethyl, Biomol GmbH, Hamburg, Germany 
eBioscience, Frankfurt, Germany 
 
R&D Systems, Wiesbaden-Nordenstadt, Germany  
 
 
R&D Systems, Wiesbaden-Nordenstadt, Germany 
Aquatex (mounting medium) Merck, Darmstadt, Germany 
β-Glycero-3-phosphate Sigma-Aldrich, München, Germany 
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BCA protein assay kit Pierce® Thermo Scientific, Bonn, Germany  
Biocoll (separating solution,  
d=1.077 g/ml) 
Biochrom AG, Berlin, Germany 
Bovine serum albumine (BSA) PAA, Cölbe, Germany 
BrdU ELISA  Roche, Mannheim, Germany 
Bromophenol blue Fluka, Neu-Ulm, Germany 
Calcein Sigma-Aldrich, München, Germany 
Cell titer blue Promega, Hamburg, Germany 
Chicken collagen type II Sigma-Aldrich, München, Germany 
Chloroform Carl Roth, Karlsruhe, Germany 
Chrome alum Prof. Amling, Hamburg, Germany 
Complete Freund’s adjuvant (CFA) Sigma-Aldrich, München, Germany 
Compound A Calbiochem, Darmstadt, Germany; 
Dr. Karolien DeBosscher, Ghent, Belgium 
4′,6-Diamidine-2-phenylindole (DAPI) AppliChem, Gattersleben, Germany 
143-10-2 1-Decanthiol  
(Technovit 9100 NEW kit) 
Heraeus Kulzer GmbH, Hanau, Germany 
Dexamethasone Sigma-Aldrich, München, Germany 
Dibenzoyl peroxide  
(Technivit 9100 NEW kit) 
Heraeus Kulzer GmbH, Hanau, Germany 
Diethylpyrocarbonate (DEPC) Carl Roth, Karlsruhe, Germany 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich, München, Germany 
Dithiothreitol (DTT)  Invitrogen, Karlsruhe, Germany 
Dulbecco's Modified Eagle Medium 
(DMEM) 
GIBCO
®
 Invitrogen, Karlsruhe, Germany 
ECL Hyperfilm 5x7 inch  GE Healthcare, München, Germany 
ECL Plus Western blotting substrate Pierce® Thermo Scientific, Bonn, Germany  
Enzyme linked immunosorbent 
assays (ELISAs) 
   ACTH (mouse) 
   Corticosterone (mouse) 
   CTX-1 (mouse) 
   Dkk-1 (human) 
 
 
Demeditec, Kiel, Germany 
IDS, Frankfurt, Germany 
R&D Systems, Wiesbaden-Nordenstadt, Germany 
R&D Systems, Wiesbaden-Nordenstadt, Germany 
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   IFN-γ (mouse) 
   P1NP (mouse) 
   TNF-α (mouse) 
R&D Systems, Wiesbaden-Nordenstadt, Germany 
Immundiagnostik, Bensheim, Germany 
R&D Systems, Wiesbaden-Nordenstadt, Germany 
Entellan Merck, Darmstadt, Germany 
Eosin G (tetrabromofluoresceine) Carl Roth, Karlsruhe, Germany 
Ethanol, absolute  VWR, Darmstadt, Germany 
Ethanol, denatures Berkel AHK, Berlin, Germany 
Ethidium bromide Serva, Heidelberg, Germany 
5x First Strand Buffer Invitrogen, Karlsruhe, Germany 
Fetal calf serum Lonza, Köln, Germany 
Fluorescent mounting medium  Dako North America Inc., Carpinteria, CA, USA 
Formaldehyde (37%) Merck, Darmstadt, Germany 
Gelatine Serva, Heidelberg, Germany 
GeneRuler 100 bp DNA ladder  Fermentas, St. Leon-Rot, Germany 
Glacial acetic acid Merck, Darmstadt, Germany 
Glycine Merck, Darmstadt, Germany 
Glycerol  Sigma-Aldrich, München, Germany 
Hank’s balanced salt solution (HBSS) PAA, Cölbe, Germany 
Hydrochloric acid (HCl) Merck, Darmstadt, Germany 
High Pure RNA Isolation Kit Roche, Mannheim, Germany 
Isopropyl Merck, Darmstadt, Germany 
2-Isopropyl-5-methylphenol (Thymol) Euro OTC Pharma GmbH, Bönen, Germany 
Ketamine 10% (100 mg/ml) Bela-pharm, Vechta, Germany 
Kodak GBX  Sigma-Aldrich, München, Germany 
L-ascorbate phosphate Sigma-Aldrich, München, Germany 
Lipopolysaccharide Sigma-Aldrich, München, Germany 
Magnesium chloride Fermentas, St. Leon-Rot, Germany 
Macrophage colony-stimulating factor 
(M-CSF) 
R&D Systems, Wiesbaden-Nordenstadt, Germany 
Mayers hemalum Merck, Darmstadt, Germany 
Minimum essential media (α-MEM) GIBCO
®
 Invitrogen, Karlsruhe, Germany 
Biochrom AG, Berlin, Germany 
Methanol Merck, Darmstadt, Germany 
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2-Methoxyethyl acetate Sigma-Aldrich, München, Germany 
Methyl methacrylate  
(Technovit 9100 NEW kit) 
Heraeus Kulzer GmbH, Hanau, Germany 
Mifepristone (RU-486)  Sigma-Aldrich, Hamburg, Germany 
Mini trans-blot filter paper Whatman, Dassel, Germany 
Naphthol-AS-BI-phosphate Serva, Heidelberg, Germany 
N,N,3,5-Tetramethylaniline  
(Technovit 9100 NEW kit) 
Heraeus Kulzer GmbH, Hanau, Germany 
Nitric acid (HNO3) Fluka, Neu-Ulm, Germany 
Non-fat dry milk Carl Roth, Karlsruhe, Germany 
Deoxyribonucleotide triphosphates 
(dNTP Mix) 
Fermentas, St. Leon-Rot, Germany 
Osteosoft® Merck, Darmstadt, Germany 
PageRuler Prestained Protein Ladder Fermentas, St. Leon-Rot, Germany 
Paraffin (Medim-Plats 58°C) Medim Histotechnologie, Buseck, Germany 
Pararosaniline (chloride) Merck, Darmstadt, Germany 
Phosphate buffered saline (PBS)  Biochrom AG, Berlin, Germany 
Penicillin/streptomycin PAA, Cölbe, Germany 
peqGOLD TriFast peqlab Biotechnologie GmbH, Erlangen, Germany 
Plexidon MW 235 (Technovit 9100) Heraeus Kulzer GmbH, Hanau, Germany 
Ponceau red Carl Roth, Karlsruhe, Germany 
Power SYBR Green PCR Master Mix Applied Biosystems, Darmstadt, Germany 
Prednisolone Sigma-Aldrich, München, Germany 
Protease inhibitor cocktail Sigma-Aldrich, München, Germany 
Random hexamer primers  Invitrogen, Karlsruhe, Germany 
RANKL recombinant mouse R&D Systems, Wiesbaden-Nordenstadt, Germany 
Reducing reagent, 20x Fermentas, St. Leon-Rot, Germany 
RNase AWAY Molecular BioProducts (ThermoScientific), Bonn, 
Germany 
RNaseOUT™ Recombinant Ribo-
nuclease Inhibitor 
Invitrogen, Karlsruhe, Germany 
Roti-histofix (4% PFA) Carl Roth, Karlsruhe, Germany 
Roti-histofix Aqua (mounting media) Carl Roth, Karlsruhe, Germany 
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RPMI 1640 with stable L-glutamine PAA, Cölbe, Germany 
Silver nitrate Carl Roth, Karlsruhe, Germany 
Slow-release pellets  
 
Innovative Research of America, Sarasota, FL, 
USA 
Sodium acetate Fluka/Sigma-Aldrich, Hamburg, Germany 
Sodium carbonate Merck, Darmstadt, Germany 
Sodium chloride Merck, Darmstadt, Germany 
Sodium dodecyl sulfate (SDS) ultra 
pure 
Carl Roth, Karlsruhe, Germany 
Sodium hydroxide Merck, Darmstadt, Germany 
Sodium nitrite Caesar & Loretz GmbH, Hilden, Germany 
Sodium thiosulfate Carl Roth, Karlsruhe, Germany 
Sulfuric acid (H2SO4) Pharmacy of the Medical Clinic Dresden, Germany 
SuperScript II reverse transcriptase  Invitrogen, Karlsruhe, Germany 
Taq-polymerase Invitek, Berlin, Germany 
Tartrate-resistant acid phosphatase 
(TRAP) Kit 
Sigma-Aldrich, München, Germany 
Tetramethylbenzidine (TMB) solution Biomedica, Wien, Germany 
Tetramethylethylenediamine (TEMED) Carl Roth, Karlsruhe, Germany 
Thymol crystals Prof. Amling, Hamburg, Germany 
Toluidine blue WALDECK GmbH & Co. KG in Münster, Germany 
Transfer membrane (Protan BA 83) Whatman, Dassel, Germany 
2,4,6-Trinitrophenol (picric acid) Morphisto Evolutionsforschung und Anwendung 
GmbH, Frankfurt/Main, Germany 
Triplex II (EDTA) Merck, Darmstadt, Germany 
Tris Carl Roth, Karlsruhe, Germany 
Triton X-100 Serva, Heidelberg, Germany 
Trypan blue Sigma-Aldrich, München, Germany 
Trypsin-EDTA PAA, Cölbe, Germany 
Tween 20 Serva, Heidelberg, Germany 
X-Ray cassette rego  Gollwitzer GmbH & CoKG, Augsburg, Germany 
Xylazine (20mg/ml) Pharma Partner, Hamburg, Germany 
Xylene cyanol Merck, Darmstadt, Germany 
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Xylene VWR, Darmstadt, Germany 
 
 
3.1.2 Animals and cells  
Animal/cell Supplier, city, country 
C57BL/6 mice (male, 24 weeks) JANVIER SAS, Le Genest Saint Isle, France 
DBA/1 mice (male, 10 weeks)  JANVIER SAS, Le Genest Saint Isle, France 
FVB/N mice (male, 12 weeks and 
female, 24 weeks) 
JANVIER SAS, Le Genest Saint Isle, France 
MLO-Y4 cells Prof. Lynda F. Bonewald, Kansas City, MO, USA 
Primary human bone marrow stromal 
cells (BMSC) 
Prof. Martin Bornhäuser, TU Dresden, Germany 
 
RAW 264.7 cells Prof. Lorenz C. Hofbauer, Marburg, Germany 
 
3.1.3 Equipment 
Instrument Supplier, city, country 
Bench Hera Safe Heraeus (Thermo Scientific), Bonn, Germany 
Blot chambers BioRad, München, Germany 
Caliper  Meyer, Eisenach, Germany 
Centrifuges 
   Centrifuge 5415D 
   Labofuge 400 
   Micro centrifuge Galaxy-Ministar 
   SIGMA 3K30  
   Table centrifuge Galaxy Mini 
 
Eppendorf, Hamburg, Germany 
Heraeus (Thermo Scientific), Bonn, Germany 
VWR, Darmstadt, Germany 
Sigma-Aldrich, München, Germany  
VWR, Darmstadt, Germany 
COP 30 tissue cool plate MEDITE GmbH, Burgdorf, Germany 
Counting chamber Laboroptik Ltd, Lancing, UK 
Drying block Schleicher & Schnell, Dassel, Germany 
Drying oven Memmert, Schwabach, Germany 
Dukalux x-tronic Kindermann & Co.GmbH , Ochsenfurt, Germany 
Electrophoresis Power EV 265 Consort, Turnhout, Belgium 
Electrophoresis chamber Mini-Protean BioRad, München, Germany 
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Embedding shapes 25mm (+ inserts) Heraeus Kulzer GmbH, Hanau, Germany 
FACSCalibur BD Biosciences, Heidelberg, Germany 
7500 Fast Real-Time PCR System Applied Biosystems, Carlsbad, CA, USA 
Fluostar Omega  BMG Labtech, Offenburg, Germany 
Fridges 
   Vitacool (+4°C)  
   Kirsch BOSCH (-20°C)  
   HERAfreeze (-80°C) 
 
Foron, Duisburg, Germany 
Bosch, Stuttgart, Germany 
Heraeus (Thermo Scientific), Bonn, Germany 
Gel chamber SHU 13 Fisherbrand, Loughborough, UK 
Hot plate shaker PHMP Grant-bio, Grants Pass, Oregon, USA 
Ice machine Ziegra, Isernhagen, Germany 
Incubator B15 Heraeus (Thermo Scientific), Bonn, Germany 
Laminar flow Köttermann, Uetze/Hänigsen, Germany 
Magnetic stirrer MR Hei-Tec Heidolph, Schwabach, Germany 
Mc Frosty Brand Products, Fulda, Germany 
Microscope Axiovert 40C  Carl Zeiss Jena, Jena, Germany 
Microtome RM2265 Leica, Nussloch, Germany 
Nano Drop ND-1000 Thermo Scientific/ PEQLAB, Erlangen, Germany 
OLYMPUS FE-4040 digital camera Olympus, Hamburg, Germany 
OsteoMeasure OsteoMetrics, Decatur, GA, USA 
pH meter 766 Knick, Berlin, Germany 
Pipetus-akku Hirschmann, Eberstadt, Germany 
Power Pac 200  BioRad, München, Germany 
pQCT, XCT Research M Stratec Medizintechnik, Pforzheim, Germany 
Professional Standard Thermal Cycler Biometra analytikjena, Göttingen, Germany 
PureLab Ultra ELGA Labwater, Celle, Germany 
Restrainer (Injection cage) Bioscape (Ebeco), Castrop-Rauxel, Germany 
Scales 
  BL 310 
  Discovery 
 
Sartorius, Göttingen, Germany  
OHAUS, Giessen, Germany 
ScanMaker i900  MIKROTEK, Willich, Germany 
Shaker Janke&Kunkel, Staufen, Germany; 
ES Edmund Bühler GmbH, Hechingen, Germany 
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Shandon Citadel 2000 Tissue 
processor  
Thermo Scientific/ PEQLAB, Erlangen, Germany 
Shandon histocentre 2 Thermo Scientific/ PEQLAB, Erlangen, Germany 
Staining line MEDITE GmbH, Burgdorf, Germany 
Steam sterilization Varioklav Typ 400 Variomag (Thermo Scientific), Bonn, Germany 
Thermomixer comfort Eppendorf, Hamburg, Germany 
Suture clips (Michel clamp) with 
appropriate tool for placing 
AGESA Herwarth-Rath Medizintechnik, Dresden, 
Germany 
Ultraturrax VDI 12 VWR, Darmstadt, Germany 
UV solo TS Imaging System Biometra, Göttingen, Germany 
VarioCAM high resolution  Carl Zeiss, Jena, Germany 
Vortex genie 2 Scientific Industries, USA 
Water bath GFL, Leipzig, Germany 
 
3.1.4 Consumables  
Consumable Supplier, city, country 
15 and 50 ml tubes Greiner BioOne, Frickenhausen, Germany 
5 ml polystyrene round bottom tube  
(Facs tubes) 
BD Biosciences, Heidelberg, Germany 
Beakers, glassware Schott Duran, Mitterteich, Germany 
Cell culture plates, dishes and flasks Greiner BioOne, Frickenhausen, Germany 
Collagen-coated cell culture flasks 
and plates 
Greiner BioOne, Frickenhausen, Germany 
Cover slips Menzel-Gläser, Braunschweig, Germany 
Cryo tubes  Brand Products, Fulda, Germany 
Dako Pen Code S2002 Dako, Glostrup, Denmark 
Embedding cassettes Engelbrecht, Edermünde, Germany 
Eppendorf tubes (2, 1.5, 0.6, 0.2 ml) Eppendorf, Hamburg, Germany 
Filter tips (1, 0.1, 0.01 ml) Biozym Scientific GmbH, Hessisch Oldendorf,  
Germany 
Forceps FST Medizintechnik, Bad Oyenhausen, Germany 
Glass/microscope slides Thermo Scientific/ PEQLAB, Erlangen, Germany 
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Leica 819 low profile microtome 
blades 
Leica, Nussloch, Germany 
Leica disposable blades TC-65 Leica, Nussloch, Germany 
Multiply® Fast PCR plate Sarstedt, Nümbrecht, Germany 
Nail polish Manhattan, Mainz, Germany 
Needles (27G) B. Braun, Melsungen, Germany 
Pasteur pipette (7 ml) VWR, Darmstadt, Germany 
Pipette tips (1, 0.2, 0.01 ml) Greiner, Solingen/ Sarstedt, Nümbrecht, Germany 
Pipettes (5, 10, 25 ml) Eppendorf, Hamburg, Germany 
Polyethylene foils Heraeus Kulzer GmbH, Hanau, Germany 
Scissors FST Medizintechnik, Bad Oyenhausen, Germany 
Syringe Omnifix-F (1, 10 ml) B. Braun, Melsungen, Germany 
 
3.2 Methods 
3.2.1 Mouse models 
3.2.1.1 Glucocorticoid-induced osteoporosis 
Female FVB/N mice and male C57BL/6 mice were purchased from Janvier SAS and kept 
following institutional guidelines. All mice (n=24) were fed a standard diet with water ad 
libitum. The local animal care committee approved all animal procedures. To induce bone 
loss in 6-months old female FVB/N mice, 60 day slow-release pellets (Fig. 9) containing 
either placebo, prednisolone (PRED; 1.25 - 30 mg), or CpdA (1.25 - 30 mg) were implanted. 
For the main experiment a pellet dose of 3.5 mg was used. Before implantation, mice were 
narcotized by intraperitoneal injection with a combination of ketamine (100 mg/kg body 
weight) and xylazine (20 mg/kg body weight).  Seven and three days before sacrifice, mice 
received two calcein (20 mg/kg) injections intraperitoneally to identify newly formed bone. 
After a total of four weeks, mice were killed to examine the effects on the skeleton.  
 
 
 
 
 
 Figure 9. Sixty-day slow release pellets containing 5, 15, and 30 mg of compound A. 
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3.2.1.2 Collagen-induced arthritis 
Male ten- to twelve-week-old DBA/1 mice were purchased by Janvier SAS and housed 
following institutional guidelines. All mice (n=80) were fed a standard diet with water ad 
libitum. The local animal care committee approved all animal procedures. Arthritis was 
induced according to the protocol of Inglis et al. [81] by collagen type II (CII) injection. 
Therefore, CII was dissolved in 0.1 M acetic acid at a concentration of 4 mg/ml by stirring 
overnight at 4°C. DBA/1 mice were immunized intradermally at the base of the tail (Fig. 10A) 
with 100 µg of CII emulsified in complete Freund’s adjuvant (CFA). Starting at day 14, mice 
were monitored every other day for clinical symptoms of arthritis. The clinical severity of 
arthritis per paw was graded according to standard evaluation procedures as follows: 0, 
normal paws; 1, slight swelling and/or erythema; 2, moderate paw swelling; 3, severe paw 
swelling (Fig. 10D-G) [76]. Further macroscopic assessment of arthritis was performed by 
determining the thickness of the hind paws every second day using calipers and the 
ascertained paw swelling was expressed as an average of both hind paws per mouse 
(Fig. 10B,C). Moreover, conventional imaging was performed using a digital camera and for 
thermal imaging a high resolution thermal imaging camera. Photographs were taken from 
healthy mice before immunization, once arthritis appeared, and 10 days after treatment. 
Therefore, mouse paws were placed concentric in the focal point of the camera. Thereafter, 
the paw temperature was measured using the software supplied with the camera. Once 
arthritis appeared, mice were randomized into one of the following groups: placebo, 
dexamethasone (DEX, 100 µg), or CpdA (300 µg) and treated every second day for ten days. 
Because of the higher potency of DEX and better solubility in water compared to PRED, we 
decided to treat the arthritic mice with DEX. Seven and two days before sacrifice, mice 
received intraperitoneal calcein injections (20 mg/kg). Animals were killed twelve days after 
onset and organs were harvested.  
 
Thirty-five mice were used for control experiments and therefore did not receive CII. 
Five mice did not receive any treatment and ten healthy mice were either treated with PBS, 
DEX (100 µg/mouse), or CpdA (300 µg/mouse) each second day for 10 days. 
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3.2.2  Structural bone analyses 
Bone mineral density and bone mass were assessed in the distal femur and fourth lumbar 
vertebra using peripheral quantitative computed tomography (pQCT). Measurement 
conditions were as follows: the voxel size was 70 μm at the distal femur (two slices at the 
trabecular region located 1 mm beneath the growth plate, one at the mid-diaphysis located 6 
mm from the growth plate) and the fourth vertebral body (two slices in the mid-vertebral 
body). Scout view image was used to determine the position of the growth plate. Trabecular 
bone mineral density was measured by setting regions of interest, using contour mode 1 and 
peel mode 20. Cortical bone mineral density was calculated with a threshold of 710 mg/cm3. 
Quality was ensured by performing control measurements using the standard and cone 
phantom, which was supplied by the manufacturer.  
 
3.2.3 Bone histology and histomorphometry 
For the histological assessment of the fixed bones and hind paws (phosphate-buffered 
formalin, 4%), two embedding methods – paraffin and methyl methacrylate – were used. 
Paraffin was used for decalcified bones and subsequent staining for hemalum/eosin G (HE) 
B 
A 
C 
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Figure 10. Induction and measurement of collagen-induced arthritis. DBA/1 mice were injected 
with chicken collagen type II emulsified in complete Freund’s adjuvant at the base of the tail (A). Paw 
swelling was determined using a commercially available caliper (B,C). The disease activity was 
determined using standard evaluation procedures (disease activity score) according to Inglis et al. 
The paws were graded as follows: 0, normal paws (D); 1, slight swelling and/or erythema (E); 2, 
moderate paw swelling (F); 3, severe paw swelling (G). C-G [76]. 
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and tartrate-resistant acid phosphatase (TRAP), undecalcified bones were embedded in 
methyl methacrylate for the detection of calcein labeling and von Kossa staining.  
 
3.2.3.1 Paraffin histology 
Before embedding in paraffin, bones were decalcified (Osteosoft®) and dehydrated in an 
ascending ethanol series (Table 1). 
 
Table 1. Ascending ethanol series for dehydration. 
 
Reagent Time 
50% ethanol 0.5 h 
65% ethanol 1.0 h 
80% ethanol 1.0 h 
80% ethanol 1.0 h 
96% ethanol 1.0 h 
96% ethanol 1.0 h 
isopropyl  1.0 h 
isopropyl  1.5 h 
xylene  1.0 h 
xylene  1.5 h 
paraffin  1.5 h 
paraffin  2.0 h 
  
Afterwards, bones were embedded in paraffin, sectioned, and mounted on coated glass 
slides. For subsequent staining, paraffin-embedded sections of the hind paws, the fourth 
lumbar vertebra, and the femur were dewaxed (xylene, 10 min) and rehydrated using an 
alcohol gradient: 2x 100% - 96% - 80% - 70% - 50% ethanol, 2 min each and rinsed in 
distilled water. TRAP staining was used to assess the number of osteoclasts per total area 
(N.Oc/T.Ar). Therefore dewaxed and rehydrated sections were rinsed with acetate buffer 
(pH 5.6) and incubated with hexoniumpararosanilin and naphthol-AS-BI-phosphate in acetate 
buffer (pH 5.6, 2.5 h, 37°C drying oven). After rinsing in distilled water before and after re-
fixation in 4% formalin (30 min), sections were counter-stained with hemalum (1 min) and 
dipped in distilled water containing 1.2% hydrogen chloride to defecate the glass slides and 
eliminate redundant hemalum. Before mounting (Aquatex), sections were rinsed with 
lukewarm tap water (10 min) to stabilize the colour. At the end, sections were coated (nail 
polish) to avoid desiccation. The infiltration area per total area (infiltration area/T.Ar) was 
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assessed using HE staining. Therefore dewaxed and rehydrated paraffin sections were 
stained with hemalum (1 min), rinsed with water and dipped in distilled water containing 1.2% 
hydrogen chloride. After rinsing in tap water (10 min), sections were exposed to eosin G 
(1 min) and dehydrated using ascending alcohol series (80% ethanol, 30 sec; 96% ethanol, 
1 min; isopropyl, 2 min). Thereafter sections were exposed two times to xylene (5 min) and 
permanently mounted (Entellan). The amount of cartilage destruction was graded on HE 
slides with a scoring system: 0, no destruction; 1, mild destruction; 2, moderate destruction; 
3, severe destruction. 
 
3.2.3.2 Methyl methacrylate histology 
For the histomorphometric analyses, fixed bones of the fourth vertebral body and the tibiae 
were dehydrated in ascending ethanol series by using the previously described machine (4 x 
80% - 4 x 96% - 4 x isopropyl, 2 h each). After pre-infiltration (1 h, 4°C) and infiltration (24 h, 
4°C), bones were embedded in methyl methacrylate and cut into 4 µm sections for 
subsequent staining and 7 µm sections for assessing the fluorescence labels (calcein). For 
both kinds of sections chrome alum gelatine coated glass slides were used. To determine the 
mineral apposition rate (MAR), the mineralized surface per bone surface (MS/BS), and the 
bone formation rate (BFR/BS), unstained sections were analyzed using fluorescence 
microscopy and the two fluorescent labels. Before analysis, sections were deplastinated with 
methoxyethyl acetate (3 x 5 min) and mounted with Entellan after exposure to xylene (5 min).  
The 4 µm sections were stained with von Kossa to analyze bone volume over total volume 
(BV/TV), trabecular number (Tb.N), trabecular separation (Tb.Sp), and trabecular thickness 
(Tb.Th). For this purpose, deplastinated slides were rehydrated using an alcohol gradient 
(100% - 100% - 96% - 80% - 70% - 50% ethanol, 2 min each), rinsed with distilled water and 
exposed to 5% silver nitrate (5 min). Afterwards, sections were exposed to sodium carbonate 
dissolved in formalin (5 min) and sodium thiosulfate (5 min), and rinsed with water in between 
(10 min). Thereafter the slides were stained with toluidine blue (1%, pH 4.5, 30 min), then 
rinsed and dehydrated (50% - 70% - 80% - 96% - 100% - 100% ethanol, 2 min each). After 
exposure to xylene (3 x 5 min), sections were mounted using Entellan. 
 
For the histomorphometric analysis the Osteomeasure software was used. 
Therefore, a total area of 144 µm2, 4 µm under the growth plate, was analyzed to determine 
different parameters such as bone surface or number of osteoclasts and osteoblasts, 
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respectively, by using a special pen and tracing the appropriate areas. Photographs were 
taken and processed with the AxioVision 3.1 program. The measurements, terminology, and 
units used for histomorphometric analysis were those recommended by the Nomenclature 
Committee of the American Society of Bone and Mineral Research [82]. 
 
3.2.4 Culture of human bone marrow-derived osteoblasts 
Following the Institutional Review Board approval and after obtaining written informed 
consent, primary human bone marrow stromal cells (BMSC) were collected from healthy 
donors (aged 22-49 years, mixed gender). The cells were obtained from the group of Prof. 
Martin Bornhäuser under an active protocol of the Institutional Review Board. They diluted 5-
7 ml bone marrow aspirate in PBS containing 0.5% human serum albumin (HSA). To 
separate mononuclear cells a 20 ml aliquot was layered over a Percoll solution (d=1.073 g/ml, 
Biocoll) and centrifuged at 900 x g for 30 min at room temperature. Recovered mononuclear 
cells were pressed through a 100 µm Nylon cell strainer (Becton Dickinson Labware) and 
washed twice in PBS-0.5% HSA. The cells were seeded into 75 cm2 flasks containing DMEM, 
10% fetal calf serum (FCS) and 1% penicillin/streptomycin (pen/strep). Human BMSC were 
grown in a humidified atmosphere of 95% air and 5% CO2. By washing with PBS-0.5% HSA, 
non-adherent cells were removed after 24 h. Every four days the medium was changed. 
BMSC were recovered after reaching 90% confluence using trypsin-EDTA and plated at a 
density of 5,000 – 6,000 cells per cm2 of surface area as passage 1 (P1) cells. Cells in 
passages 3-5 were used [30,83]. To generate osteogenic cells, 70% confluent cells were 
switched to basal medium supplemented with 100 µM ascorbate phosphate, 5 mM β-glycero-
3-phosphate, and 10 nM DEX for 21 days. Before treatment cells were starved (DMEM 
containing 1% FCS and 1% pen/strep) over night and then stimulated with DEX, another GC, 
which is more potent compared to PRED, or CpdA at concentrations ranging from 0.01 to 1 
µM for 48 h and 72 h, respectively. In some experiments cells were pre-treated with 1µM RU-
486 for 1 h, an established GR antagonist [30].  
 
3.2.5 Primary murine bone marrow stromal cell culture 
Primary murine BMSC were yielded by flushing the femora with medium and maintaining 
those cells in DMEM with 10% FCS and 2% pen/strep. To generate osteogenic cells, 70% 
confluent cells were treated with basal medium supplemented with 100 µM ascorbate 
phosphate and 5 mM β-glycero-3-phosphate for 21 days. Before treatment, cells were 
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switched to starving media (DMEM containing 1% FCS and 1% pen/strep) overnight and then 
treated with DEX or CpdA (both 0.1 µM) for 48 h and 72 h, respectively. To mimic an 
inflammatory situation, cells were treated with 1 µg/ml lipopolysaccharide (LPS) 1 h after 
treatment with DEX or CpdA.  
 
3.2.6 Culture of murine osteocyte-like cells (MLO-Y4) and co-culture with 
osteoclast precursor cells (RAW 264.7) 
 
The osteocyte-like cell line MLO-Y4 (murine long bone osteocytes [84]) was cultured on 
collagen-coated cell culture flasks in α-MEM with 10% FCS and 1% antibiotics/antimycotics 
(containing streptomycin sulfate, Penicillin G, and amphotericin B). Before treatment cells 
were starved overnight and then treated with DEX or CpdA (both 0.1 µM) for 48 h. For time-
kinetic experiments cells were treated for 3, 6, 12, 24, or 48 h using 0.1 µM DEX. In some 
experiments, cells were pre-treated for 1 h with 1 µM RU-486. To provide for inflammatory 
stimuli, cells were treated with 1 µg/ml LPS after a 1 h pre-treatment with DEX or CpdA. For 
immunofluorescence analysis of RANKL, the cells were grown on glass slides in α-MEM with 
10% FCS and 1% antibiotics/antimycotics for three days. After switching to serum-reduced 
medium (1% FCS) overnight, cells were treated with 0.1 µM DEX or CpdA, or 1 µM RU-486.  
 
Murine RAW 264.7 cells were cultured in α-MEM containing 10% FCS and 1% 
pen/strep. For osteoclast co-culture experiments, MLO-Y4 cells were maintained in α-MEM 
with 10% FCS and 1% antibiotics/antimycotics and plated at a density of 1,500 cells/cm². 
Before treatment cells were switched to starving media for 6 h and then treated with DEX or 
CpdA (both 0.1 µM – 1 µM). After 17 h treatment, RAW 264.7 cells were seeded at a density 
of 12,500 cells /cm² on top of the MLO-Y4 cells and cultured for another 6 days. Following 
fixation in acetone/citrate buffer, cells were stained for TRAP. TRAP-positive cells with three 
or more nuclei were counted as osteoclasts. 
 
3.2.7 Proliferation assay 
Peripheral blood mononuclear cells (PBMCs) were isolated from the spleen of arthritic mice 
using Biocoll density centrifugation. Therefore spleens were minced and carefully layered 
over a Percoll solution (d=1.077 g/ml, Biocoll) and centrifuged at 1000 x g for 10 min at room 
temperature. PBMCs were washed twice in PBS and cultured in RPMI with 10% FCS and 1% 
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antibiotic/antimycotic. After 48 h of stimulation with CII (50 µg/ml) or an anti CD3 antibody 
(100 ng/ml) as positive control, half of the supernatant was collected for the measurement of 
IFN-γ and TNF-α. Subsequently, BrdU labeling solution (100 µM) was added to the remaining 
cell culture medium. During the final 24 h, the pyrimidine analogue BrdU is incorporated 
instead of thymidine into the DNA of proliferating cells. After 24 h, cell proliferation was 
analyzed using a BrdU ELISA (Cell Proliferation ELISA, BrdU (colorimetric)®) according to the 
manufacturer’s instructions. 
 
3.2.8 RNA isolation, RT, and real-time RT-PCR 
RNA was extracted by crushing the bone (femora and tibiae, or paw) in liquid nitrogen and 
collecting the bone powder in Trifast (Peqlab). For the RNA extraction from the spleen, the 
organ was minced and mononuclear cells were isolated by subjecting the tissue to Biocoll 
density centrifugation as described previously (3.2.7). The mononuclear cell fraction was 
lysed in Trifast. For the extraction of RNA from colon, the organ was minced using an 
Ultraturrax and lysed in Trifast. RNA from mature human and murine BMSC (cultured 
21 days) was also isolated using Trifast after washing twice with PBS. RNA isolation was 
performed according to the manufacturer’s protocol. RNA from murine osteocytes (MLO-Y4 
cells) as well as from immature human and murine BMSC (cultured 0-14 days) was isolated 
using the HighPure RNA extraction kit from Roche according to the manufacturer’s 
instructions. The amount of RNA was measured using the Nano Drop ND-1000. Five-hundred 
ng RNA were used for reverse transcription (RT-PCR) using Superscript II. The produced 
complementary DNA (cDNA) was subsequently used for SYBR green-based real-time PCR 
reactions using a standard protocol (Applied Biosystems). Primer sequences are summarized 
in Table 2. The used PCR conditions were 50°C for 2 min and 95°C for 10 min followed by 40 
cycles with 95°C for 15 s and 60°C for 1 min. For the assessment of the melting curve the 
following program was used: 95°C for 15 s, 60°C for 1 min and 95°C for 30 s. The results 
were calculated according to the ΔΔ-CT method [85] and are presented as x-fold increase 
relative to β-actin.  
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Table 2. Primer used for the quantitative analysis of gene expression. 
 
Targeted gene  Primer sequences  5’-3’ 
hu ACTB f 
r 
CCAACCGCGAGAAGATGA 
CCAGAGGCGTACAGGGATAG 
mu ACTB 
 
f 
r 
GATCTGGCACCACACCTTCT 
GGGGTGTTGAAGGTCTCAAA 
mu ALP f 
r 
ATCCAACTGACACCAAGCAG 
TGAGCGGTTCCAAACATACC 
mu CASP-3 f 
r 
GGAGCAGCTTTGTGTGTGTG 
GGCAGTAGTCGCCTCTGAAG 
hu Dkk-1  
 
f 
r 
AGCACCTTGGATGGGTATTC 
CACACTTGACCTTCTTTCAGGAC 
mu Dkk-1  f 
r 
GAGGGGAAATTGAGGAAAGC 
AGCCTTCTTGTCCTTTGGTG 
mu IL-6 
 
f 
r 
ACTTCCATCCAGTTGCCTTC 
ATTTCCACGATTTCCCAGAG 
mu OCN f 
r 
GCGCTCTGTCTCTCTGACCT 
ACCTTATTGCCCTCCTGCTT 
mu OPG f 
r 
CCTTGCCCTGACCACTCTTA 
ACACTGGGCTGCAATACACA 
mu OSCAR 
 
f 
r 
CACACACACCTGGCACCTAC  
GAGACCATCAAAGGCAGAGC 
mu RANKL 
 
f 
r 
GCAGAAGGAACTGCAACACA 
GATGGTGAGGTGTGCAAATG 
mu RUNX2 
 
f 
r 
CCCAGCCACCTTTACCTACA 
TATGGAGTGCTGCTGGTCTG 
mu Sost f 
r 
CGGAGAATGGAGGCAGAC 
GTCAGGAAGCGGGTGTAGTG 
mu TNF-α 
 
F 
r 
CCTCTTCTCATTCCTGCTTGTG 
CACTTGGTGGTTTGCTACGAC 
mu TRAP f 
r 
ACTTGCGACCATTGTTAGCC 
AGAGGGATCCATGAAGTTGC 
 
ACTB – beta-actin, ALP – alkaline phosphatase, CASP-3 – caspase 3, DKK-1 – dickkopf-1, IL-6 –  
interleukin 6, OCN – osteocalcin, OPG – osteoprotegerin, OSCAR – osteoclast-associated receptor, 
RANKL – receptor activator of nuclear factor κB ligand, RUNX2 – runt-related transcription factor 2, 
SOST – sclerostin, TNF- α – tumor necrosis factor-α, TRAP – tartrate resistant acid phosphatase. 
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3.2.9 Western Blot 
Human BMSC were washed twice with PBS and scraped in lysis buffer containing 20 mM 
Tris/HCl pH 7.4, 1% SDS, and 1:10 of a protease inhibitor cocktail. Lysates were processed 
through a 24-gauge needle, centrifuged, and stored at -80°C. Protein extraction from the 
colon was realized using an Ultraturrax and lysing it in Trifast. Protein isolation was 
performed according to the manufacturer’s protocol and the amount of protein was 
determined using the BCA protein assay kit.  
 
For Western Blot analysis of the Wnt inhibitor Dkk-1 in treated human BMSC and 
apoptotic proteins in colon tissue of treated arthritic animals, lysates were boiled for 5 min at 
98°C. Ten µg of proteins were loaded on a 15% SDS-PAGE and transferred onto a 0.2 µm 
nitrocellulose membrane. Subsequently after blocking for 1 h with 5% non-fat dry milk in Tris-
buffered saline with 1% tween-20 (TBS-T), membranes were incubated with an anti-human 
Dkk-1 antibody (1:500) or an anti-murine caspase-3 antibody (1:1,000), an anti-murine 
caspase-7 antibody (1:1,000), or an anti-human/murine GAPDH antibody (1:2,000) overnight 
and washed three times with TBS-T. Thereafter, incubation with an appropriate HRP-
conjugated IgG antibody (anti-rabbit IgG; anti-mouse IgG) for 1 h followed. To visualize the 
proteins, membranes were washed with TBS-T and incubated for 1 min with Super Signal to 
enhance chemiluminescence. The proteins were then visualized by detecting the signal on 
ECL Hyperfilms. GAPDH was used as loading control.  
 
3.2.10 Immunofluorescence  
MLO-Y4 cells, which were cultured on glass slides (3.2.6), were washed with PBS and fixed 
with methanol (100%) for 10 min. After three washing steps using PBS, glass slides were 
blocked with 1% BSA in PBS for 30 min and exposed to an anti-murine PE-labeled RANKL 
antibody (1:50) for 48 h. Subsequently, cells were washed three times, stained with DAPI 
(1:1,000) for 5 min, and washed again for 15 min. Afterwards glass slides were embedded in 
a small droplet of mounting medium on object slides. Using the Zeiss Axio Imager M.1 
fluorescence microscope, slides were examined and photographs were taken and processed 
with the AxioVision 3.1 program. 
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3.2.11 ELISA 
Pro-collagen type 1 N-terminal peptide (P1NP), a serum marker of bone formation, the bone 
resorption marker C-terminal collagen type I crosslinks (CTX-1), interferon-γ (IFN-γ), tumor 
necrosis factor-α (TNF-α) as well as Dkk-1 were measured in the serum of mice or in the 
supernatant of treated human BMSC and T-cells isolated from murine spleen, respectively, 
using commercially available ELISAs.   
 
For the assessment of anti-collagen antibodies, serum of arthritic mice from different 
treatment groups was collected. The assay was performed according to Inglis et al [81]. 
Therefore, 96-well plates were coated with 5 µg/ml CII dissolved in 0.05 M Tris-HCl/0.2 M 
NaCl overnight at 4°C. After washing the plate three times using PBS/Tween (0.05% Tween 
20) and blocking with 2% bovine serum albumin (BSA) for 1 h at room temperature, test sera 
(diluted 1:5,000 in PBS/Tween) were incubated for 2 h at room temperature. Following six 
washing steps with PBS/Tween, bound IgG1 and IgG2a were detected by incubation with 
HRP-conjugated anti-mouse IgG1 or IgG2a 1:1,000 in PBS/Tween for 1 h at room 
temperature, respectively. After three additional washing steps, TMB solution was added to 
each well and the reaction was stopped using sulphuric acid when a change of colour was 
detectable. Optical density was measured at 450 nm with a reference wave length of 540 nm. 
By deducting the value of 540 nm from the 450 nm value, each serum sample was 
determined. 
 
 The measurement of adrenocorticotropic hormone (ACTH) and corticosterone in the 
serum of mice was carried out by Dr. Valéria Lamounier-Zepter (Division of Molecular 
Endocrinology, Department of Medicine III, Faculty of Medicine, TU Dresden).  
 
3.2.12 Flow cytometry 
The murine osteocyte-like cells MLO-Y4 (3.2.6) were grown on collagen-coated 6-well-plates 
in α-MEM for 3 days. After a 48 h treatment with 0.1 µM DEX, CpdA, or pre-treatment with 
1 µM RU-486 in serum-reduced medium (1% FCS), cells were washed with PBS and blocked 
in 3% BSA in PBS containing 5% FCS for 30 min. Thereafter the cells were exposed to an 
anti-murine PE-labeled RANKL antibody (1:50) for 30 min at room temperature. Following 
three washing steps with PBS/FCS (5%) and converting the cells into the relevant FACS 
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tubes, RANKL-positive cells were measured using the FACSCalibur. For analysis of the 
gained data CellQuest Pro was used.  
 
3.2.13 Statistic evaluation 
Results are presented as means  standard deviation (SD). All experiments were repeated at 
least three times. Statistical evaluations were performed using a Student’s t-test for 
comparison of two groups or one-way analysis of variance (ANOVA) for time- and dose-
curves as well as comparison of more than two groups. P-values < 0.05 were considered 
statistically significant. 
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4  Results 
4.1 Compound A maintains bone mineral density in mice 
4.1.1 Dose finding study of compound A  
In order to assess the influence of the novel selective GR agonist, CpdA, on bone, we 
performed several dose finding experiments and compared them with prednisolone (PRED). 
We implanted slow-release pellets (Innovative Research of America) in FVB/N and C57BL/6 
mice of different ages (3 and 6 months old) and analyzed their response to CpdA. The pellet 
doses ranged from 1.25 - 30 mg PRED or CpdA. We found that FVB/N mice receiving pellets 
with 1.25 and 2.5 mg CpdA lived normally until day 21 (end of experimental setup), whereas 
mice with the 5 mg pellet died one day after the implantation. Mice receiving pellets 
containing 10, 15, and 30 mg CpdA died at the day of implantation (Fig. 11). Before they died, 
mice were groggy, showed ruffled hair and a cowering posture. By contrast, FVB/N mice 
receiving PRED did not show such features and all PRED-treated mice survived the 
treatment period. Furthermore, our experiments showed that C57BL/6 mice were not able to 
tolerate even low doses of CpdA as all mice died one day after the intervention (data not 
shown).   
  
 
 
 
 
 
 
 
 
 
To identify an adequate positive control GIO model, we investigated bone loss by performing 
peripheral QCT (pQCT) analysis in mice of different strains, ages, and sexes in response to 
PRED treatment. Therein, 24 weeks old female FVB/N mice lost the highest amount of bone 
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Figure 11. Survival curve of FVB/N mice treated with CpdA. 60 day slow-release pellets containing 
1.25 (n=8), 2.5 (n=8), 5 (n=5), 10 (n=5), 15 (n=5), or 30 mg (n=5) compound A (CpdA) were implanted 
in 12 weeks old female FVB/N mice.  
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(Fig. 12). Whereas 12-weeks old male mice lost only 2% BMD, 24 weeks old female FVB/N 
mice lost 10% of bone. Importantly, 3.5 mg PRED were not sufficient to induce bone loss in 
C57BL/6 mice. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Consequently, we decided to use 6 months old female FVB/N mice with 60 day slow-release 
pellets containing 3.5 mg of the respective substance for 28 days for our main experiment.  
 
4.1.2 Compound A maintains bone density and histomorphometric 
parameters in mice 
 
After having established the experimental setup for our main experiment, we used pQCT to 
determine the effects of CpdA on bone. We showed, that in contrast to PRED, which 
significantly decreased the total density in the femur by 9% (p<0.05; Fig. 13A) and in the 
vertebral body by 10.5% (p<0.01; Fig. 13C), CpdA did not influence this parameter at either 
site. Furthermore, the trabecular bone density of these two sites was also not reduced by 
CpdA (Fig. 13B,D), whereas PRED potently reduced trabecular bone density in the femur by 
23.5% (p<0.05) and in the vertebral body by 19.6% (p<0.01), respectively. The 
histomorphometric analysis confirmed these results. PRED treatment led to a 21% (p<0.05) 
decrease in bone volume over tissue volume (BV/TV), whereas CpdA-treated mice showed 
no reduction (Fig. 14A). Additionally, CpdA did not affect the structural parameters trabecular 
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Figure 12. Total bone mineral density (BMD) measurement in prednisolone (PRED) treated 
mice. Peripheral quantitative computed tomography was performed to analyze the total BMD in the 
femur of 12 or 24 weeks old FVB/N and C57BL/6 mice. Mice were treated with either vehicle (CO) or 
2.5 mg PRED for 3 weeks or with 3.5 mg PRED for 4 weeks, respectively. n=4-8; *p<0.05 vs. CO. 
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number, thickness, and separation (Fig. 14B-D) which were for the most part negatively 
influenced by PRED [44].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To gain more insights into how CpdA affects biomechanical properties of bone, we 
determined the cross-sectional moment of inertia (CSMI) using pQCT, which is a common 
surrogate marker for bone strength [86–89]. Up to 70% of bone strength has been shown to 
be predicted by the cross-sectional moment of inertia. Furthermore, this parameter strongly 
correlates with bending stiffness (R2=0.96). Therefore, this unit of measurement has become 
an important surrogate marker for the analysis of bone strength [86–89]. PRED treatment 
decreased the CSMI by 8.3%, albeit non-significantly (p=0.055), while the results of CpdA 
treatment were similar to that of control mice (Fig. 14E). Thus, PRED decreased bone 
Figure 13. Compound A (CpdA) maintains bone mineral density (BMD) in mice. Peripheral 
quantitative computed tomography was performed to analyze the total BMD (Tt. Dn) in the femur (A) 
and fourth lumbar vertebrae (L4; C), as well as the trabecular density (Tb. Dn) in the femur (B) and in 
the vertebral bodies (D) of treated mice (vehicle (CO), prednisolone (PRED), or CpdA). n=6-7. 
*p<0.05; **p<0.01 vs. CO [44]. 
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mineral density and suppressed CSMI-based bone strength in mice, whereas CpdA did not 
influence bone density, structure, and strength [44]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14. Compound A (CpdA) maintains structural parameters as well as the cross-sectional 
moment of inertia (CSMI), an indicator of bone strength in mice. Using von Kossa staining, we 
determined the bone volume over tissue volume (BV/TV; (A)), the trabecular number (Tb.N; B), 
thickness (Tb.Th; C), and separation (Tb.Sp; D). Peripheral quantitative computed tomography was 
performed to analyze the CSMI in the femur of treated mice (E). n=6-7; *p<0.05 vs. CO [44]. 
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4.1.3 Compound A has no negative effects on bone formation or resorption 
parameters 
 
To investigate whether the bone-sparing effect of CpdA is interceded via support of 
osteoblast or osteoclast functions, respectively, a structural and histological bone analysis 
was performed. By fluorescence microscopy of the two fluorescent calcein labels, the mineral 
apposition rate (MAR) was determined. MAR was reduced by 50% (p<0.05) in PRED-treated 
mice whereas the CpdA pellets did not affect this parameter (Fig. 15A). To demonstrate this, 
exemplary calcein double labels are shown for each treatment group (Fig. 15C). A larger 
space between the fluorescence labels and a stronger signal compared to the sections of the 
GC-treated mice were found in the animals treated with the placebo or CpdA pellets. 
Corresponding to the histological data, the detrimental effects of PRED on bone formation 
were also shown by a 34% (p<0.01) decrease of procollagen type 1 amino-terminal 
propeptide (P1NP), a serum bone formation marker (Fig. 15B).  
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
Figure 15. Histomorphometric and serum osteoblast parameters are unaffected by compound 
A (CpdA). Calcein double labeling was performed to determine the influence of prednisolone (PRED) 
and CpdA on the mineral apposition rate (MAR; A). Representative double labels for each treatment 
group are shown (E). Serum procollagen type 1 amino-terminal propeptide (P1NP; B) was assessed 
using a commercially available ELISA. n=6-8. *p<0.05; **p<0.01 vs. CO [44].  
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TRAP staining was performed to assess the osteoclast number per bone surface (Oc.N). By 
quantification of the TRAP-positive osteoclasts, a 3-fold increase (p<0.01) in the number of 
these cells was shown in the PRED-treated mice, whereas CpdA showed no such effect 
(Fig. 16A,C). Moreover, these results were in line with the analysis of the serum marker C-
terminal collagen crosslinks (CTX-1). Mice treated with PRED pellets showed an increase in 
this bone resorption marker by 26% (p<0.05), whereas CpdA did not induce CTX-1 
(Fig. 16B). These data suggest, that in comparison to PRED, CpdA neither impairs bone 
formation nor stimulates bone resorption [44].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.1.4 Compound A does not influence osteoblast and osteoclast markers in 
bone tissue 
 
To further analyze whether CpdA locally affects bone remodeling parameters, the expression 
of genes involved in bone formation and resorption processes in the bone tissue (femora) 
Figure 16. Histomorphometric and serum osteoclast parameters are unaffected by compound 
A (CpdA). Using tartrate-resistant acid phosphatase (TRAP) staining we determined the number of 
osteoclasts (Oc. N; A) in the treated animals. Representative images are shown (C). Serum carboxy-
terminal collagen crosslinks (CTX-1; B) were assessed using a commercially available ELISA. n=6-8. 
*p<0.05; **p<0.01 vs. CO [44]. 
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were investigated. While CpdA did not impair the bone formation markers runt-related 
transcription factor 2 (RUNX2), alkaline phosphatase (ALP), and osteocalcin (OCN), PRED 
decreased those by 64%, 59%, and 45% (p<0.05; Fig. 17A), respectively [44].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Additionally, PRED caused a significant (5-fold; p<0.05) increase in the RANKL/OPG ratio 
whereas CpdA did not alter the ratio (Fig. 17B). This effect was caused by a significant down-
regulation of OPG (CO: 1.64 ± 0.86; PRED: 0.72 ± 0.37; CPDA: 1.62 ± 0.75) and concurrent 
up-regulation of RANKL (CO: 2.15 ± 1.73; PRED: 3.50 ± 1.38; CPDA: 2.21 ± 0.65). Moreover, 
neither substance affected the expression of the osteoclast marker genes osteoclast-
associated receptor (OSCAR) and TRAP (Fig. 17B). Hence, these results show that CpdA 
has no impact on osteoblast and osteoclast markers in the bone tissue [44]. Because CpdA 
did not show any unfavourable effects on bone remodeling parameters, the expression of 
pro-inflammatory cytokines was investigated to confirm its in vivo efficacy. In fact, the GR 
agonist suppressed the gene expression levels of TNF-α (-35%) and IL-6 (-56%; p<0.01) in 
mononuclear cell extracts from the spleen just as well as PRED (Fig. 18).  
 
 
 
Figure 17. Compound A (CpdA) does not influence osteoblast or osteoclast markers in the 
bone tissue. Real-time PCR analysis was performed for runt-related transcription factor 2 (RUNX2), 
alkaline phosphatase (ALP), and osteocalcin (OCN), as well as for osteoclast-associated receptor 
(OSCAR) and tartrate-resistant acid phosphatase (TRAP) in murine femoral bone tissue (vehicle (CO), 
prednisolone (PRED) or CpdA). The receptor activator of NF-κB ligand (RANKL)/osteoprotegerin 
(OPG) ratio was calculated by dividing RANKL expression by OPG expression as determined by real-
time PCR. Gene expression levels were normalized to β-actin. n=6-7; *p<0.05 vs. CO [44]. 
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In addition, CpdA was also effective in reducing lipopolysaccharide (LPS)-induced expression 
of TNF-α and IL-6 in bone marrow stromal cells and murine osteocyte-like cells (Table 3). 
 
Table 3. Expression levels of pro-inflammatory genes in murine bone marrow stromal cells 
(BMSC) and murine osteocytes (MLO-Y4 cells). 
 Murine BMSC MLO-Y4 cells 
Treatment IL-6 TNF-α IL-6 TNF-α 
    CO 1.17 ± 1.53 1.83 ± 0.66 1.00 ± 0.21 1.00 ± 0.06 
    DEX 0.48 ± 0.24 1.13 ± 0.44 1.20 ± 0.53 0.21 ± 0.05 
    CPDA 0.62 ± 0.35 0.61 ± 0.32* 1.92 ± 0.32 1.03 ± 0.26 
    LPS 121 ± 41.3 23.3 ± 4.75 18.41 ± 3.36 2.28 ± 0.75 
    LPS + DEX 3.87 ± 0.83
##
 5.70 ± 0.50
###
 3.11 ± 0.31
##
 0.41 ± 0.02
#
 
    LPS + CPDA 3.00 ± 1.89
##
 4.21 ± 1.64
###
 3.00 ± 1.52
###
 0.33 ± 0.06
#
 
BMSC – bone marrow stromal cells, CO – control, DEX – dexamethasone, CPDA – compound A, LPS 
– lipopolysaccharide,  IL-6 – interleukin 6, TNF- α – tumor necrosis factor-α. *p<0.05 vs. CO;
 #
p<0.05; 
##
p<0.01; 
###
p<0.001 vs. LPS [44].  
 
4.1.5 Compound A does not increase the RANKL/OPG ratio in MLO-Y4 cells 
Because of the recent discovery that osteocytes are the main source of RANKL in bone 
[90,91] and to further verify that CpdA does not influence the RANKL/OPG ratio in murine 
Figure 18. Compound A (CpdA) suppresses the expression of pro-inflammatory cytokines in 
spleen-derived mononuclear cells.  Real-time PCR analysis was performed for mRNA expression of 
the pro-inflammatory genes tumor necrosis factor-α (TNF-α; A) and interleukin 6 (IL-6; B) in spleen-
derived mononuclear cells of treated mice (vehicle (CO), prednisolone (PRED), or CpdA). Gene 
expression levels were normalized to β-actin. n=5-8; *p<0.05; **p<0.01 vs. CO [44]. 
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bone tissue, the modulation of this ratio by DEX and CpdA in osteocytes was investigated. 
DEX treatment of MLO-Y4 cells induced a 9-fold (p<0.01) increase in the RANKL expression, 
whereas CpdA did not (Fig. 19A). Furthermore, DEX reduced OPG mRNA levels by 59% 
(p<0.05; Fig. 19C). As a result, the RANKL/OPG ratio was enhanced 22-fold (p<0.001) by GC 
treatment but remained unchanged with CpdA. Pre-treatment with the GR antagonist RU-486 
reversed the induction of the RANKL/OPG ratio (Fig. 19B). Moreover, time kinetics were 
performed to determine whether the RANKL-inducing effect of DEX occurs directly or 
indirectly. Due to the fact that the RANKL/OPG ratio was already increased 4-fold (p<0.01) 
after 3 h, DEX treatment seemed to induce the RANKL expression directly. Further, the ratio 
increased over time until it peaked after 24 h (Fig. 19D) [44].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19. Compound A (CpdA) does not increase the receptor activator of NF-κB ligand 
(RANKL)/osteoprotegerin (OPG) ratio in MLO-Y4 cells. Real-time PCR analysis was performed to 
determine mRNA levels of RANKL (A) and OPG (C) in MLO-Y4 cells after treatment with 
dexamethasone (DEX; 0.1 µM) or CpdA (0.1 µM), and RU-486 (1 µM; B) for different durations (3 h – 
48 h; D). The RANKL/OPG ratio was calculated by dividing RANKL by OPG expression as 
determined by real-time PCR. Gene expression levels were normalized to β-Actin. n=4. *p<0.05; 
**p<0.01; ***p>0.001 vs. CO. 
###
p<0.001 vs. DEX [44].  
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Using an anti-RANKL antibody for immunofluorescence staining and flow cytometry, the 
RANKL-inducing effect of DEX was confirmed at protein level (Fig. 20A-C). Thereby RANKL 
was increased 3-fold (p<0.001) in DEX-treated cells and this induction was also reversed by 
pre-treatment with RU-486. CpdA showed no effect on RANKL production. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20. Dexamethasone (DEX) increases the receptor activator of NF-κB ligand 
(RANKL)/osteoprotegerin (OPG) ratio in MLO-Y4 cells and induces osteoclast formation. MLO-
Y4 cells were cultured for 3 days and upon starvation, cells were stimulated for 48 h with 0.1 µM DEX 
or compound A (CpdA) and/or 1 µM RU-486. Immunofluorescence images show RANKL stained in 
red. Nuclei were stained with DAPI (blue). Magnification: 400x (A). Using flow cytometry the 
percentage of RANKL-positive cells was determined (B,C). MLO-Y4 cells were cultured in α-MEM 
and under serum-free conditions, cells were stimulated with 0.1 µM DEX or CpdA. After 15 h, RAW 
264.7 cells were seeded on top of the MLO-Y4 cells and cultured in α-MEM containing 10 ng/ml of 
RANKL. Tartrate-resistant acid phosphatase staining was performed to count the number of 
osteoclasts (Oc.N). As a positive control, RAW 264.7 cells were cultured alone in α-MEM containing 
50 ng/ml RANKL (D). n=3. *p<0.05; ***p<0.001 vs. CO; 
##
p<0.01 vs. DEX [44]. 
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To investigate the functional relevance of the RANKL-inducing effect of DEX in osteocytes, 
MLO-Y4 cells were treated with either DEX or CpdA and cultured together with osteoclast 
precursor cells (RAW 264.7) to determine osteoclast development. Osteocytes treated with 
DEX induced a 1.8-fold (p<0.05) increase in osteoclast number, whereas CpdA treated MLO-
Y4 cells did not increase osteoclast development (Fig. 20D). Hence, these results illustrate 
that maintaining a physiological RANKL/OPG balance could be part of the bone-sparing 
character of CpdA [44]. 
 
4.1.6 Compound A does not transactivate Dkk-1 
To further examine possible underlying mechanisms of the GC-induced suppression of bone 
formation, one important inhibitor of the Wnt signaling pathway, Dkk-1, was analyzed. 
Therefore, its expression level after treatment with GC or CpdA was determined in bone 
tissue of treated mice (placebo, PRED, or CpdA), as well as in human BMSC and murine 
osteocytes. Dkk-1 mRNA expression in bone tissue was increased 2-fold (p<0.05) in mice 
treated with PRED, whereas CpdA did not change Dkk-1 mRNA levels (Fig. 21A). Similarly, 
DEX increased Dkk-1 3-fold (p<0.05) in human BMSC and 2-fold (p<0.01) in MLO-Y4 cells, 
while CpdA exerted no effect on the Wnt inhibitor.  
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Figure 21. Compound A (CpdA) does not stimulate dickkopf-1 (Dkk-1) expression levels. Gene 
expression analysis of Dkk-1 mRNA expression in murine femoral bone tissue (n=6-8) of treated mice  
(placebo (CO), prednisolone (GC), or compound A (CpdA)) as well as in human bone marrow stromal 
cells (BMSC) and in murine osteocyte-like cells (MLO-Y4; A), which were treated with either 
dexamethasone (GC) or CpdA (both 0.1 µM). Gene expression levels were normalized to β-Actin n=3-
4; *p<0.05; **p<0.01 vs. CO; [44]. 
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Furthermore, DEX treatment induced a dose- and time-dependent increase of Dkk-1 
expression in human BMSC (Fig. 22A, B). By pre-treating with RU-486, this effect was 
blocked (Fig. 22C) [44]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The dose- and time-dependent up-regulation of Dkk-1 by DEX was also shown by analyzing 
the supernatants of treated BMSC using ELISA (Fig. 23A, B) and by Western Blot analysis of 
Dkk-1 (Fig. 23C). In brief, these data suggest that CpdA does not influence Dkk-1 expression 
in bone tissue or any other bone cell types, while GC increase the expression dose- and time-
dependently [44]. 
 
 
 
 
 
 
 
 
Figure 22. Dickkopf-1 (Dkk-1) expression levels were dose- and time-dependently increased in 
human bone mineral stromal cells (hBMSC). Gene expression analysis of Dkk-1 mRNA expression 
in hBMSC, which were treated with dexamethasone (DEX; 0.01 – 1 µM) for different time points (48, 
72 h) (A,B). To inhibit glucocorticoid actions, cells were pre-treated with RU-486 (1 µM; (C)). Gene 
expression levels were normalized to β-Actin. n=3-4; *p<0.05 vs. CO; 
#
p<0.05 vs. DEX [44]. 
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4.1.7 Compound A does not influence the hypothalamic-pituitary axis 
To determine whether CpdA also acts via activation of the negative feedback regulation of 
hormone release in the hypothalamic-pituitary axis, the production of adrenocorticotropic 
hormone (ACTH) and corticosterone was determined. PRED significantly influenced the 
hypothalamic-pituitary axis as it decreased corticosterone levels in the serum of treated mice 
by 65% (p<0.01), while ACTH levels were not significantly modified. In contrast to that, CpdA 
did not change corticosterone and ACTH levels suggesting that it has no influence on the 
hypothalamic-pituitary axis.  
 
 
Figure 23. Time- and dose-dependent regulation of dickkopf-1 (Dkk-1) protein expression by 
dexamethasone (DEX). Dkk-1 protein levels were determined in the supernatants of human bone 
marrow stromal cells (BMSC) after treatment with different doses of DEX (0.01 – 1 µM) for different 
time points (A,B) using a commercially available ELISA. Representative image of Dkk-1 (29 kDa) and 
GAPDH (34 kDa) as assessed by Western blot analysis (C) of human BMSC treated with different 
doses of PRED (0.01 – 1 µM) are shown. n=3-4; **p<0.01; ***p<0.001 vs. CO [44]. 
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4.2 Effects of compound A on bone metabolism and inflammation in mice 
with collagen-induced arthritis 
4.2.1 Arthritis induction and dose finding study of compound A  
In order to investigate whether CpdA also exerts bone-sparing effects in an inflammatory 
setting, we induced arthritis with CII and treated arthritic mice with CpdA. To stay within the 
same mouse strain, we first used FVB/N mice, which were immunized with CII. Unfortunately, 
FVB/N mice did not develop any signs of arthritis, not even after injection of the doubled CII 
dose or after booster injections. Additionally, we tried to induce arthritis using another arthritis 
model, the K/BxN serum transfer model. However, also using this passive T cell-independent 
model, FVB/N mice did not develop arthritis. Therefore, arthritis was induced in DBA/1 mice, 
the common strain for arthritis induction using CII. To assess the anti-inflammatory capacities 
of CpdA, dose finding experiments were performed. Two different doses – 150 µg and 300 µg 
per mouse – were used according to previous literature [76,78]. We found that the higher 
dose of CpdA achieved better anti-inflammatory properties compared to the lower dose as 
the disease activity score (Fig. 24A) as well as the paw swelling (Fig. 24B) were reduced by 
300 µg CpdA more efficiently. Consequently, we identified the higher dose as suitable for our 
collagen-induced arthritis model.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24. Disease activity score and paw swelling in CpdA-treated arthritic mice. The disease 
activity score (A) and the paw thickness (B) were determined every second day from arthritis onset 
until day 35. n=3-6. 
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4.2.2 Compound A reduces disease activity of collagen-induced arthritis 
After having established the appropriate dose for our experiments and in order to assess the 
anti-inflammatory effects of the selective GR agonist, CpdA, we treated arthritic mice with 
CpdA (300 µg), DEX (100 µg), or PBS for 10 days. While DEX reduced signs of arthritis, 
CpdA was not as efficient as the GC. CpdA decreased the disease activity score by 43% 
(p<0.05) whereas DEX reduced it by 72% (p<0.01) as compared to disease onset (Fig. 25A, 
26B left panel). The reducing effect of CpdA on paw swelling (-12%) failed to reach 
significance (p=0.06), while DEX reduced paw swelling significantly by 22% (p<0.01) as 
compared to day 0 (Fig. 25B).  
 
 
 
 
 
 
 
 
 
 
 
 
By using a high resolution thermal imaging camera the paw temperature was determined. As 
expected, paws of arthritic mice were 3.9°C (+13%; p<0.001) warmer compared to paws of 
mice without arthritis. DEX treatment induced a reduction of the paw temperature by 75%, 
almost back to baseline levels (baseline: 25.8 °C; arthritis: 29.8°C; after treatment: 26.8 °C, 
p<0.05) whereas CpdA only tended to decrease it by 44% (Fig. 26A,B right panel). However, 
no differences in weight were detected (Fig. 26C). Thus, these data show that CpdA 
possesses anti-inflammatory effects, but is weaker compared to DEX [92]. 
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Figure 25. Compound A (CpdA) reduces signs of collagen-induced arthritis. The disease activity 
score (A) and the paw thickness (B) were determined at baseline (B), disease onset (d0), and every 
other day during the treatment period of 10 days (d2-10). n=6-8; *p<0.05; **p<0.01 vs. day 0 treatment 
(onset of arthritis) [92]. 
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4.2.3  Compound A inhibits T cell response 
The T cell response of type II collagen specific T cells isolated from the treated mice was 
determined to further analyze the anti-inflammatory potential of the selective GC receptor 
agonist CpdA. Therefore, their proliferation rate and IFN-γ-production was measured. We 
found that T cells isolated from PBS-treated mice and exposed to CII ex vivo, responded with 
nearly the same proliferation rate as cells that were exposed to anti-CD3 (positive control). T 
cells originating from non-arthritic mice (CO) did not show a CII-specific response (Fig. 27A). 
Figure 26. Compound A (CpdA) shows reducing effects on paw temperature. The paw 
temperature (A) and the body weight (C) were determined at baseline (B), disease onset (d0) and 
every other day during the treatment period of 10 days (d2-10). A conventional and a thermal imaging 
camera was used to take pictures at different stages of the disease. One exemplary mouse per group 
is shown (B). n=6-8; *p<0.05; **p<0.01 vs. day 0 treatment (onset of arthritis) [92]. 
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In comparison to PBS, DEX and CpdA significantly limited T cell proliferation after stimulation 
with CII (Fig. 27A). In accordance to that, the IFN-γ concentration was decreased in the 
supernatant of PBMCs isolated from DEX- and CpdA-treated mice. A significantly higher 
amount of IFN-γ was produced by cells obtained from PBS-treated mice (Fig. 27B). 
Additionally, the production of TNF-α showed a similar pattern as IFN-γ production of TNF-α 
was lowered in PBMCs isolated from DEX- or CpdA-treated mice (16.53 ± 4.15 and 11.80 ± 
2.49 pg/ml, respectively) compared to PBMCs from PBS-treated animals (111.85 ± 0.79 
pg/ml) [92].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 27. Compound A (CpdA) inhibits the collagen type II-specific T cell response. Peripheral 
blood mononuclear cells were isolated from the spleens of treated animals (PBS, dexamethasone 
(DEX), and CpdA) and stimulated with collagen type II (50 µg/ml) or an anti-CD3 antibody (100 ng/ml), 
as positive control. Proliferation was analyzed using BrdU after 48 h (A) and supernatants were 
collected to measure IFN-γ production (B) using a commercially available ELISA. Collagen-antibodies 
(IgG2a) were measured in the serum of treated DBA/1 mice (C) and immunized FVB/N mice (D). n=6-
8; *p<0.05; **p<0.01; ***p<0.001 vs. CO; ##p<0.01 vs. PBS [92]. 
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Interestingly, the production of collagen auto-antibodies was not changed after treatment with 
the substances (Fig. 27C), which was possibly due to the fact, that the arthritis-resistant 
FVB/N mouse strain, immunized with CII, produced auto-antibodies compared to non-
immunized mice (Fig. 27D). Hence, CpdA can inhibit CII-specific T cell proliferation and IFN-
γ-production in arthritic mice [92]. 
 
4.2.4 Effects of compound A on histopathological features of inflammation 
Histomorphometric analyses of HE-stained sections of the paws were performed to determine 
cellular infiltrates in the joints to further characterize the anti-inflammatory features of the 
used SEGRA. Vehicle-treated arthritic mice showed massive infiltrations (Fig. 28A,B), 
whereas the joint structure of paws from collagen-naïve control animals was intact. Treatment 
with DEX led to a 87% (p<0.05) lower infiltration area (0.07 mm²) compared to the vehicle-
treated group (0.55 mm²). CpdA treatment was less potent compared to DEX (Fig. 28A, B). 
While CpdA did not protect from cartilage destruction (Fig. 28C), DEX decreased it by 77% 
(p<0.001) compared to the vehicle-treated group [92]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 28. Compound A (CpdA) reduces histopathological features of inflammation. HE staining 
was performed to visualize the infiltration area (B) in the paws of mice of the different treatment groups 
(CO – control; PBS – vehicle; DEX – dexamethasone; CPDA – compound A). Representative images 
are shown (A). Magnification: 50-fold. Cartilage destruction was determined by scoring the surface 
integrity of the articular cartilage (C). n=5-8; *p<0.05; ***p<0.001 vs. CO; 
###
p<0.001 vs. PBS [92]. 
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The number of osteoclasts was assessed using TRAP staining. CpdA and DEX both inhibited 
the number of osteoclasts by 68% and 81% (p<0.05), respectively (Fig. 29A,B). Furthermore, 
we determined the expression of TNF-α in the joint tissue. DEX-treatment led to a lower 
expression of TNF-α (-71%, p<0.05) as compared to PBS-treatment. Additionally, CpdA-
treated mice showed a 63% decrease of TNF-α expression (p=0.07; Fig. 29C). Even though 
CpdA has an anti-inflammatory character, it appears to be weaker than the classical GC DEX 
[92]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.2.5 Compound A does not prevent inflammation-induced bone loss 
After having assessed the anti-inflammatory properties of CpdA, the next step was to analyze 
its effect on bone density parameters. Therefore, pQCT measurement of murine femora was 
performed. As expected, arthritis alone displayed detrimental effects on bone density in the 
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Figure 29. Compound A (CpdA) reduces the number of osteoclasts (N.Oc). Tartrate-resistant acid 
phosphatase staining was performed to determine the number of osteoclasts (B) in the paws of the 
treated animals (CO – control; PBS – vehicle; DEX – dexamethasone; CPDA). Representative images 
are shown (A). Magnification: 200-fold. Gene expression analysis of TNF-α/ -actin mRNA expression 
in paws from non-arthritic and arthritic mice which were treated either with PBS, DEX, or CpdA. n=5-8; 
*p<0.05; ***p<0.001 vs. CO; 
#
p<0.05 vs. PBS [92]. 
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femur as it decreased the total bone density by 15% (p<0.01) and the trabecular density by 
24% (p<0.05), respectively (Fig. 30A,B). Moreover, CpdA led to a similar bone loss as 
observed in the PBS-treated mice (CpdA: -15%, p<0.05 and PBS: -29%, p<0.05 vs. control). 
To discriminate whether the decreased bone mass in CpdA-treated arthritic mice was due to 
direct effects of CpdA on bone, non-arthritic control mice were treated with the same 
treatment regimen as arthritic mice. None of these mice lost bone mass (Fig. 30C,D) [92]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 30. Compound A (CpdA) does not prevent inflammation-induced loss of bone density. 
Peripheral quantitative computed tomography was performed to analyze the total (A) and trabecular 
bone mineral density (B) in the femur of non-arthritic controls (CO) and arthritic mice treated with 
vehicle (PBS), dexamethasone (DEX) or CpdA. n=6-10. Healthy control mice were treated for 10 days 
with PBS, DEX or CpdA to determine the treatment effects on total and trabecular bone density in 
non-arthritic mice (C,D). n= 5-8. *p<0.05 vs. CO; 
#
p<0.05; 
##
p<0.01 vs. PBS [92]. 
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Histomorphometry confirmed the pQCT data as the bone volume/total volume (BV/TV) in the 
femur was decreased by 48% (p<0.01) in arthritic mice treated with PBS, whereas the DEX-
treated mice did not lose bone mass. A 58% (p<0.01) decrease in bone mass was observed 
in CpdA-treated animals (Fig. 31A). Besides, treatment with vehicle and CpdA had negative 
effects on the structural parameters trabecular thickness, separation, and number. In 
contrast, the trabecular structure was maintained by DEX treatment (Fig. 31B-D) [92].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Using TRAP staining, the osteoclast number/total area (Oc.N/T.Ar) and the osteoclast 
surface/bone surface (Oc.S/BS) was assessed. The number of osteoclasts was induced 3.5-
Figure 31. Compound A (CpdA) does not prevent inflammation-induced loss of bone structure. 
Using tartrate-resistant acid phosphatase staining of the femora of non-arthritic controls (CO) and 
arthritic mice treated with vehicle (PBS), dexamethasone (DEX) or CpdA, we determined bone volume 
over total volume (BV/TV; A) as well as the structural parameters trabecular number (Tb.N; B), 
trabecular thickness (Tb.Th; C), and trabecular separation (Tb.Sp; D). n=5-8. *p<0.05; **p<0.01; 
***p<0.001 vs. CO; 
#
p<0.05 vs. PBS [92]. 
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fold (p<0.05) and the osteoclast surface 4.4-fold (p<0.01) in arthritic animals compared to 
control animals. Treatment with both substances prevented an increase in the number of 
osteoclasts (-80% and -55%, p<0.05) and the osteoclast surface (-62%, p<0.05 and -29%, 
p>0.05) (Table 4). While arthritis or DEX treatment did not influence the bone formation rate 
per bone surface (BFR/BS), CpdA treatment decreased the BFR by 85% (p<0.01). 
Interestingly, this was not found in healthy control mice (Table 4). Additional parameters are 
listed in Table 4 [92]. 
 
Table 4. Histomorphometric analysis of murine fourth vertebral body, tibiae, and femora using 
the Osteomeasure software of unstained and stained bone sections. 
 
L4 PBS DEX CpdA 
BV/TV (%) 10.59 ± 2.81 10.49 ± 3.02 7.97 ± 2.27 
MAR (µm/d) 0.03 ± 0.02 0.02 ± 0.02 0.006 ± 0.001* 
BFR/BS (µm
3
/µm
2
/d) 0.008 ± 0.005 0.004 ± 0.003 0.001 ± 0.0004* 
Oc.S/BS (µm
2
) 1.87 ± 2.27 0.12 ± 0.27* 2.66 ± 2.27 
Oc.N 6.80 ± 10.85 1.00 ± 1.91 14.17 ± 10.07 
Oc.N/T.Ar (1/mm) 8.36 ± 8.82 0.61 ± 1.26* 9.84 ± 6.99 
Tb.Th (µm) 31.06 ± 6.79 33.83 ± 8.09 34.37 ± 10.55 
Tb.Sp (µm) 261.61 ± 59.52 214.06 ± 58.80 246.36 ± 90.10 
Tb.N (1/mm) 3.52 ± 0.62 4.21 ± 0.97 3.86 ± 1.10 
Tibiae    
BV/TV (%) 4.69 ± 2.47 7.81 ± 2.05* 6.82 ± 1.68 
MAR (µm/d) 0.89 ± 0.17 0.95 ± 0.21 0.59 ± 0.19 
BFR/BS (µm
3
/µm
2
/d) 0.31 ± 0.07 0.22 ± 0.19 0.16 ± 0.05 
Tb.Th (µm) 23.76 ± 2.43 35.93 ± 6.65*** 26.57 ± 2.92 
Tb.Sp (µm) 588.11 ± 240.60 441.79 ± 105.27 383.19 ± 96.40* 
Tb.N (1/mm) 1.91 ± 0.84 2.17 ± 0.43 2.56 ± 0.58 
Femur    
BV/TV (%) 8.13 ± 3.41 12.77 ± 5.41 6.64 ± 3.67 
Oc.S/BS (µm
2
) 9.44 ± 3.89 1.90 ± 1.60*** 4.32 ± 1.52** 
Oc.N 9.86 ± 7.01 4.13 ± 4.36 7.75 ± 5.87 
Oc.N/T.Ar (1/mm) 22.54 ± 12.15 8.59 ± 9.08* 16.15 ± 12.24 
Tb.Th (µm) 24.40 ± 9.25 29.74 ± 8.74 20.52 ± 5.10 
Tb.Sp (µm) 291.33 ± 69.69 212.86 ± 44.21* 334.18 ± 114.42 
Tb.N (1/mm) 3.33 ± 0.88 4.23 ± 0.72* 3.10 ± 1.06 
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L4 (CO)    
BV/TV (%) 13.36 ± 3.62 14.44 ± 3.23 13.85 ± 3.88 
MAR (µm/d) 2.20 ± 1.69 4.54 ± 5.02 2.70 ± 3.21 
BFR/BS (µm
3
/µm
2
/d) 0.58 ± 0.43 0.49 ± 0.54 0.58 ± 0.68 
Tb.Th (µm) 42.05 ± 5.81 40.22 ± 2.48 40.03 ± 5.97 
Tb.Sp (µm) 282.03 ± 49.15 247.02 ± 49.96 260.59 ± 67.55 
Tb.N (1/mm) 3.14 ± 0.48 3.56 ± 0.60 3.45 ± 0.69 
 
BFR/BS – bone formation rate/bone surface, BV/TV – bone volume/total volume, CpdA – compound A, 
CO – non-arthritic control animals treated with PBS, DEX, or CpdA, DEX – dexamethasone, L4 – 
fourth vertebral body, MAR – mineral apposition rate, Oc.N – number of osteoclasts, Oc.N/T.Ar – 
number of osteoclasts/total area, Oc.S/BS – osteoclast surface/bone surface, PBS – vehicle, Tb.Th – 
trabecular thickness, Tb.N – trabecular number, Tb.Sp – trabecular separation, TRAP – tartrate-
resistant acid phosphatase. n=4-8 *p<0.05; **p<0.01; ***p<0.001 vs. PBS.  
 
Even though local bone formation indices were not affected by DEX, it reduced the serum 
marker of bone formation P1NP by 45% (p<0.01) in arthritic mice and by 51% (p<0.05) in 
non-arthritic mice. CpdA, on the other hand, did not influence this parameter (Fig. 32A,C). 
CTX-1, the serum marker of bone resorption, was decreased by DEX by 34% (p<0.05) and 
not affected by CpdA in arthritic mice. This marker was not affected in non-arthritic control 
mice by either substance (Fig. 32B,D). Thus, these data suggest that the weaker anti-
inflammatory properties of CpdA together with its neutral effects on bone may not be 
adequate to compensate inflammation-induced bone loss while the potent anti-inflammatory 
effects of DEX may maintain bone mass [92].  
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4.2.6 Compound A treatment is associated with diarrhea in arthritic mice 
During the arthritis experiment, diarrhea was observed in 56% of the CpdA-treated mice 
which may point towards gastrointestinal toxicity. This was not the case for PBS- and DEX-
treated mice (PBS: 0/0; DEX: 0/0; CpdA: 5/9). To further analyze these symptoms, the effect 
of CpdA on apoptotic genes in colonic tissue was examined. Whereas CpdA induced a 2.7-
fold increase in caspase-3 expression (p=0.08), DEX did not alter caspase-3 (Fig. 33A). 
Western blot analysis showed that caspases-3 and -7 were activated in CpdA-treated animals 
but not in PBS- or DEX-treated mice as indicated by the presence of cleavage products 
(Fig. 33B). In conclusion, these data indicate that CpdA exerts pro-apoptotic effects on colon 
tissue. 
Figure 32. Dexamethasone (DEX) reduced serum bone formation marker. Serum of non-arthritic 
controls (CO; C,D) and arthritic mice (A,B) treated with vehicle (PBS), DEX or compound A (CpdA) 
was used to determine procollagen type 1 amino-terminal propeptide (P1NP; A,C) and carboxy-
terminal collagen cross-links (CTX-1; B,D) using commercially available ELISAs. n=7-10. *p<0.05; 
**p<0.01 vs. PBS [92]. 
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  CO         DEX       CPDA 
Figure 33. Compound A (CpdA) increases gene expression of pro-apoptotic factors in colon 
tissue. Gene expression analysis of caspase-3 mRNA expression was performed in colon tissue of 
mice that were treated with either PBS, dexamethasone (DEX), or CpdA. Gene expression levels were 
normalized to -actin (A). Representative images of caspase-3, caspase-7, and GAPDH as assessed 
by Western blot analysis of murine colon tissue are shown. Arrows indicate caspase cleavage 
products (B). n=6-8. 
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5  Discussion 
5.1 The bone-sparing effects of compound A 
Up to 50% of patients develop fractures as a consequence of GC-induced osteoporosis, a 
frequent form of secondary osteoporosis and one of the most common side effects of GC 
treatment [69,93]. Because of that, extensive research has been conducted to develop new 
selective GR agonists that show an improved risk/benefit ratio due to their selective actions 
on transrepression over transactivation [76,78,79]. Even though there are several studies 
demonstrating the impressive anti-inflammatory effects of CpdA in experimental models of 
autoimmune neuritis [80], multiple sclerosis [79], and collagen-induced arthritis [76], no 
studies have investigated its effects on bone metabolism. Therefore, the skeletal influence of 
CpdA was examined in an experimental model of GC-induced osteoporosis.  
 
While bone mineral density and trabecular parameters were not affected by CpdA, 
PRED reduced these parameters in the femur and fourth lumbar vertebrae. Similar adverse 
effects of GC treatment on bone density were already shown in several publications 
[45,56,73,94,95]. To gain molecular insights into the functional consequence of intact bone 
remodeling after CpdA treatment, we aspired to determine bone strength. Thus, data on the 
cross-sectional moment of inertia (CSMI), which has been shown to predict up to 70% of 
bone strength and strongly correlates with bending stiffness (R2=0.96) was assessed. This 
parameter, assessed by pQCT, has become an accepted surrogate marker for bone strength 
[86–89]. In our experimental setting, PRED tended to suppress the second moment of inertia, 
while the values of the CpdA-treated mice were almost equal to that of control-treated mice, 
indicating that in addition to lowering bone mass PRED also tends to impair bone strength. 
Thus, our data underline the negative influence of GC on bone strength. The detected bone-
sparing properties of CpdA are in agreement with a previous study by Owen et al. showing 
that AL-438, another selective GR modulator, has growth plate-sparing effects in 
chondrocytes and ex vivo cultures of fetal metatarsal organ cultures [96]. Additionally, 
previous in vitro findings from our group showed that CpdA induced proliferation while 
reducing apoptosis of mature osteoblasts, and maintained osteoblast differentiation, even 
when treated at higher doses. These data confirm the results shown within this thesis, that 
CpdA does not affect bone formation or resorption parameters [30,75]. To finally establish 
that CpdA indeed exerted immunosuppressive effects on lymphocytes using the dose and 
route of CpdA administration in this study we determined the expression of pro-inflammatory 
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cytokines (TNF-α, IL-6), as best possible surrogate markers, in spleen tissue of treated mice. 
Both substances were able to suppress baseline cytokine expression compared to the 
vehicle-treated animals. Moreover, CpdA was able to suppress LPS-induced cytokine 
expression in osteocytic cells in vitro equally well as DEX. Thus, these data combined with 
our previous data demonstrating the anti-inflammatory potential of CpdA in several 
osteogenic cell types in vitro [30,75] strongly support the potent capacity of CpdA to suppress 
basal and inflammation-induced cytokine expression.  
  
 Amongst other factors, the balance of RANKL and OPG is critical for maintaining 
bone mass. In past years, the effects of GC on the RANKL/OPG ratio have been investigated 
in detail [30,35,43,45]. For instance, a recent study demonstrated that GC treatment inhibits 
OPG production while stimulating mRNA levels of RANKL in various human osteoblastic 
lineage cells [43]. Another study showed that GC enhance osteoclastogenesis by inhibiting 
OPG and concurrently stimulating RANKL expression leading to increased 
osteoclastogenesis [35]. Moreover, a previous study from our lab confirmed these results and 
furthermore underlined the neutral effects of CpdA on this cytokine ratio [30]. Finally, GC-
induced bone loss is prevented by blocking excessive RANKL using neutralizing antibodies, 
suggesting that this pathway is in fact critical for the induction of GC-induced bone loss 
[43,73]. Within this thesis, PRED treatment enhanced the RANKL/OPG ratio in the bone 
tissue of mice, which was accompanied by an increased number and activity of osteoclasts. 
In this study, a two-fold increase in the number of osteoclasts after PRED treatment was 
detected while earlier studies only showed a smaller or no increase of osteoclast numbers 
[56,73]. Until now, the reason for this discrepancy is unknown but it is interesting to notice 
that the FVB/N mouse strain used here showed a two-fold induction of osteoclasts together 
with the highest loss of bone density (11%). In contrast to that, C57BL/6 and Swiss Webster 
mice lost only 6-7% bone density and showed no significant alterations of osteoclast number 
[56,73]. Despite the fact that other factors might also contribute to the regulation of 
osteoclasts in GC-induced bone loss, the varying regulation of osteoclast numbers by GC 
may depend on the used mouse strains [44].  
 
 Our recent findings already showed that CpdA has no inducing effects on the 
RANKL/OPG ratio in MSC-derived osteoblasts, fibroblast-like synoviocytes or SaOS-2 cells, 
whereas it was induced by conventional GC [30,75]. In line with that, other studies reported 
similar positive effects on maintaining the RANKL/OPG ratio for other SEGRAs, including 
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AL-438 and ZK216348 [94]. Taking into account that osteocytes are the major RANKL 
producers in adults and thereby contribute to bone remodeling [90,91], we focused on 
osteocytes [97]. Using the murine osteocyte-like cell line MLO-Y4, we showed that CpdA also 
maintains the RANKL/OPG ratio, whereas DEX induced a 30-fold induction. This RANKL-
inducing effect of DEX was further shown to be mediated directly, as 3 h after stimulation with 
DEX the RANKL/OPG ratio was already significantly increased. Hence, these data suggest 
that osteocytes may play an important role in GC-induced bone loss by controlling the 
RANKL/OPG ratio [44]. Since the discovery of Zhao and colleagues in 2002, that osteocytes 
stimulate and support osteoclast formation and activation [98], the logical next step was to 
investigate the influence of DEX- and CpdA-treated osteocytes on osteoclast formation. 
Therefore murine osteocytes treated with DEX or CpdA were co-cultured with RAW 264.7 
cells [98]. DEX treatment led to an increased osteoclast formation compared to CpdA- or non-
treated cells. This is in line with our results showing a pro-osteoclastic effect of DEX by 
increasing the RANKL/OPG ratio in contrast to CpdA [44]. Thus, osteocytes may be critical 
regulators of GIO by altering the RANKL/OPG ratio, a hypothesis that needs to be tested in 
future appropriate in vivo studies.  
 
Since Wnt signaling plays an important role in osteoblast differentiation and bone 
formation [31], its regulation by GC was addressed. Wnts are secreted glycoproteins involved 
in embryogenesis and tissue differentiation, and are also particularly important for bone 
biology. The Wnt signal is tightly regulated by extracellular antagonists including members of 
the Dkk-1 and sFRP family, Wif-1 and Sost [31]. Ohnaka et al. showed that DEX increased 
Dkk-1 expression in primary cultured human osteoblasts. Furthermore, blocking of Dkk-1 by 
RNAi prevented GC-induced bone loss in mice, suggesting an important role of Dkk-1 in the 
suppression of osteoblast functions by GC [15,31]. Similar to Dkk-1, GC also increase sFRP-
1 and thereby suppress osteogenesis [14,15,99]. Because of the emerging evidence of the 
involvement of the Wnt signaling pathway in the pathogenesis of GIO, we investigated the 
regulation of Dkk-1 in more detail and similar to other studies showed that PRED increased 
Dkk-1 expression in femoral bone tissue. Corresponding to the Dkk-1 up-regulation, the 
expression of Ocn was decreased by PRED, indicating suppressed osteoblast functions. 
Furthermore, we demonstrated that human BMSC and murine osteocytes treated with DEX 
showed a time- and dose-dependent increase in Dkk-1 expression, which is consistent with 
previous studies [14–16], showing that Dkk-1 is up-regulated by DEX in primary cultured 
human osteoblasts and murine osteoblast cell lines through transcriptional regulation. 
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Additionally, the GC-mediated increase in Dkk-1 levels was strictly dependent on the GR as 
the induction of Dkk-1 could be prevented by pre-treatment with the GR antagonist RU-486. 
Thus, this data show that similar to previously published studies, the expression of Dkk-1 is 
robustly induced by GC. In contrast, CpdA did not enhance Dkk-1 expression in vivo or in 
vitro. Therefore, the inability to induce Dkk-1 expression may reflect an important mechanism 
to prevent GC-induced bone loss [44].  
 
 To determine whether CpdA affects the hypothalamic pituitary adrenal axis, the 
concentrations of ACTH and corticosterone in the serum of treated mice were measured. In 
contrast to the expected reduced ACTH levels in the PRED treated mice, which were also 
shown in several publications [65,100,101], we detected no alterations of ACTH serum levels. 
This may be explained by the treatment duration of the substances as we determined serum 
ACTH concentrations at the end of the experimental set-up after 4 weeks treatment whereas 
Schäcke et al. as well as Reuter and colleagues analyzed the hormone levels just after 6 h or 
5 days of treatment, respectively [65,100]. In 1999, Louw and Swart showed already the 
decrease of ACTH levels after 30 days of CpdA treatment, which turned to be normal after 
day 40. They stated that the ACTH concentration showed no significant after the treatment 
period [101]. In contrast to that the corticosterone level in serum of mice was decreased after 
PRED treatment, suggesting that the high concentration of PRED in the mice induced a 
negative feedback leading to decreased production of corticosterone. CpdA, however, did not 
alter ACTH and corticosterone serum levels, indicating its independence from the 
hypothalamic pituitary axis. This may explain the overall neutral effects of CpdA compared to 
classical GC. 
 
In summary, the results shown within the first part of this thesis indicate that, 
compared to classical GC, CpdA has bone-sparing properties at several levels, including 
bone density and mass, structure, and remodeling, which may result from preserving 
osteoblast functions and maintaining a physiological RANKL/OPG balance [44]. 
 
5.2 The anti-inflammatory potential of compound A 
One of the reasons for the development of SEGRAs was the expected improved risk/benefit 
ratio, which was confirmed for CpdA in respect to glucose and bone metabolism [44,76]. 
Schäcke and Schottelius performed seminal work on the side effect profile of SEGRAs [65]. 
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They showed that ZK216348, another SEGRA, reduced skin thickness and skin-breaking 
strength significantly less than PRED. Furthermore, systemic effects were also lower 
compared to the conventional GC as reduction of body-weight gain and adrenal weight were 
decreased after SEGRA treatment. Additionally, ZK216348 led to a significantly lower 
decrease in thymus and spleen weight and did not induce an increase in blood glucose levels 
[65]. Similarly, the anti-inflammatory potential of CpdA was also demonstrated in various 
murine models of chronic inflammation [76,78,79]. One of these studies used the collagen-
induced arthritis model and showed that the anti-inflammatory properties of CpdA are based 
on the inhibition of GR dimerization [76]. Furthermore two studies using an animal model for 
multiple sclerosis, the experimental autoimmune arthritis, demonstrated the therapeutic 
effects of CpdA [78,79]. Because none of these studies investigated its effects on bone 
metabolism, we set out to study its bone-sparing potential in an inflammatory setting using 
the collagen-induced arthritis model. The results showed that whereas DEX potently 
decreased arthritis, CpdA moderately ameliorated signs of arthritis, including the disease 
activity score and the T cell response [92]. This is in accordance with previous studies, 
indicating that CpdA decreases parameters of the Th1 immune response and reduces 
inflammation [100,102].  Despite its anti-inflammatory effects, it should be noted that the 
conventional GC was more efficient in blocking inflammation as evident by the lower paw 
temperature and the smaller extent of cellular infiltrates in the synovium and cartilage 
damage [92]. The latter effect is perhaps the result of the stronger suppression of osteoclast 
activation by DEX as compared to CpdA. In line with these data, Dewint et al. also reported 
that CpdA was less potent in reducing synovial inflammation and cartilage destruction as 
compared to DEX, which completely prevented joint destruction in the paws [76].       
 
 In the first part of this work, the effect of CpdA on the skeleton was examined and it 
was demonstrated that in contrast to a classical GC, CpdA was able to maintain bone mass 
in a mouse model of GC-induced bone loss [44]. However, because this was done in healthy 
mice, we then determined the bone density parameters of arthritic mice. As expected, we 
found that arthritis alone had a negative effect on total and trabecular bone density in the 
femur. Interestingly, CpdA-treated mice lost similar amounts of bone as PBS-treated mice. 
However, this was not due to CpdA treatment per se, as non-arthritic DBA/1 mice treated with 
CpdA did not experience bone loss. In contrast to CpdA, DEX treatment prevented bone loss, 
which was most likely due to the potent suppression of inflammation, thus, preventing the 
bone-destructive effects of arthritis. This effect was not the reason of the possible positive 
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effects of DEX on bone, as DEX treatment of non-arthritic mice for a similar treatment period 
did not alter bone density.  
 
Because these data are in contrast to the results of the first part [44], the next step 
was to examine whether the treatment period of 10 days was too short to induce bone loss. 
Therefore, we analyzed the effects of DEX and CpdA over a period of 28 days in healthy 
DBA/1 mice, similar to the FVB/N mice used in the GIO study. Strikingly, bone mineral 
density also remained unchanged with this treatment regimen, suggesting that the DBA/1 
strain is not susceptible to GC-induced bone loss. Of note, the bone formation-suppressing 
effects of DEX were still present in DBA/1 mice, as the serum bone formation marker P1NP 
was significantly reduced in DEX-treated animals, but not by CpdA [92]. Thus, although this 
model may not be adequate to study the loss of bone mineral density, suppression of bone 
formation as a surrogate marker of the bone-destructive effects of GC may be applicable. 
 
In summary, we were able to demonstrate the anti-inflammatory properties of CpdA 
in DBA/1 mice, but our control experiments using GC in healthy DBA/1 mice revealed that 
this strain is not susceptible to GC-induced bone loss and is therefore not suitable to study 
GIO. In another approach to reconcile GIO and arthritis, the collagen-induced arthritis model 
was used to induce arthritis in the GIO susceptible FVB/N strain, but despite aggressive 
treatment strategies, these mice did not develop arthritis (data not shown). A previous study 
already reported the observed resistance of FVB/N mice to the development of arthritis and 
therewith was confirmed in our hands [103]. Hence, the used DBA/1 strain represents a 
potential limitation of our study as it does not allow the concurrent study of anti-inflammatory 
and skeletal effects of GC. An animal model that is appropriate for the concurrent study of 
GC-induced bone loss and arthritis would be ideal, but is currently unavailable [92]. Thus, the 
suppression of basal or LPS-induced levels of IL-6 and TNF-α, which is shown within the first 
project, may be the best possible surrogate marker. 
  
Finally, thermal imaging was used as a novel method for the evaluation of arthritis in 
mice. The data obtained by thermal imaging corresponded well to the disease activity score 
and the paw thickness. In fact, it was able to detect differences in the potency between CpdA 
and DEX, which were otherwise only captured by histological examinations of cellular 
infiltrates in the paw joints, but not by the disease activity score or paw swelling. This method 
used for the quantitative measurement of joint inflammation in humans was already described 
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by Collins et al. in 1974 [104]. They developed a system for obtaining multi-isothermal scans 
of joints by thermography. After analysis of the isothermal areas, a thermographic index was 
generated. With this system they detected an increase of this index in RA patients, which 
could be reduced after GC treatment [104]. Later the potential usefulness of a novel thermal 
imaging technique to evaluate and monitor inflammatory arthritis activity in small joints was 
investigated by Brenner and colleagues using rat models [105]. Furthermore, they determined 
whether thermal changes can be used to detect preclinical stages of synovitis. They found a 
significant correlation between thermal measurements and arthritis activity while showing that 
the technique was highly sensitive as warmth and oedema were analyzed in an area less 
than half the size of a human interphalangeal joint [105]. Based on these results, more 
studies were initiated to characterize new techniques such as a hand-held thermal imaging 
device, which was tested in a preclinical model of general inflammation and a model of RA 
[106]. This study underlines the advance of the new, rapid, highly-reproducible method to 
quantify the degree of inflammation in animal models of inflammatory diseases. Moreover, 
they describe the possibility to detect pharmocodynamic responses in paw temperature. This 
suggests that thermal imaging may be a useful tool for new diagnostic procedures [106].  
Nevertheless, it is important to recognize the possible limitations of this method. Critically 
important is the room temperature and the animals themselves, which cannot be 
standardized well in an animal experimentation setting [106]. In humans, however, this may 
require optimization. Nevertheless, our data support thermal imaging as a new method for 
evaluating arthritis in mice, but further studies are necessary to fully explore the potential of 
thermal imaging [92]. 
 
Taken together the results from the arthritis experiments confirm the anti-
inflammatory potential CpdA, but indicate that it is less potent compared to conventional GC. 
Whether the advantage of SEGRAs such as CpdA in experimental models of GC-induced 
bone loss can also be translated into clinical applications remains to be elucidated [92]. 
 
5.3 Limitations of this study  
This work describes the relative bone-sparing and anti-inflammatory properties of CpdA, 
however, our data also suggest that CpdA has unfavourable attributes such as its narrow 
therapeutic window and potentially negative effects on the gastrointestinal tract. 
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One major drawback of CpdA is its narrow therapeutic window, which has already been 
described in other publications as well [76,79,100]. Our pilot study, which was performed in 
order to identify an appropriate dose, further confirmed this fact. Here, we implanted 60 day 
slow-release pellets with doses ranging from 1.25 to 30 mg of placebo, PRED [56,73], and 
CpdA, respectively, in 12 or 24 weeks old male or female FVB/N or C57BL/6 mice for 21 
days. Implantation of pellets containing small doses of CpdA (1.25 – 2.5 mg) did not affect 
mouse health and behaviour. However, FVB/N mice receiving 5 mg CpdA or more showed 
tousled hair and a cowering posture before they died shortly after implantation or one day 
later, indicating toxic effects of CpdA at higher doses. In contrast to that, PRED treated 
animals survived the whole treatment period of 21 days, regardless of the dose. These 
observed effects could be due to the different chemical structures of the two substances, 
which are responsible for the release from the pellets. Despite the declaration of the 
manufacturer that the same amount of substance is released for the indicated time period, it 
appeared that CpdA was either released faster initially as compared to later time points, 
resulting in immediate high concentrations of CpdA, or it was released faster as compared to 
PRED. Additional investigations to determine the real release of the substances over time 
have not been performed, but would possibly underline this assumption. Swart et al., who 
already described CpdA as a non-steroidal synthetic analogue of a natural substance, 
emphasized on its relatively unstable character and pointed out, that CpdA quickly 
decomposes to reactive phenyl aziridines contributing to the toxic effects of CpdA [107]. After 
a comprehensive dose-finding study, we decided to choose a smaller dose (3.5 mg) for our 
experimental set-up. Besides the dose-finding study, we also compared the influence of age, 
sex, and strain. While we did not detect differences between male and female mice according 
to bone loss (data not shown), we found older mice better responding to GC treatment 
compared to younger mice. This agrees with the findings of Weinstein and Manolagas, 
reporting that the peak spinal bone mass is reached between 3 and 5 months of age [56,108]. 
The largest difference, however, was found between the strains. While FVB/N mice tolerated 
3.5 mg CpdA pellets well, C57BL/6 mice died after CpdA implantation of even lower dosages 
suggesting that this strain does not tolerate CpdA. Moreover, our preliminary experiments 
showed that 3.5 mg PRED was insufficient to induce bone loss in this mouse strain. However, 
previously published [73] and subsequent own studies (data not shown) showed that doses 
over 5 mg PRED are necessary to induce bone loss in C57BL/6 mice. Since we showed that 
FVB/N mice are not susceptible for the collagen-induced arthritis model and to better 
combine the two disease models, we further tested the bone-sparing potential of CpdA in 
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DBA/1 mice using 60 day slow-release pellets as described in the first part of the thesis. 
Unfortunately, the very same subcutaneous pellet dose that we used in the FVB/N strain was 
toxic in DBA/1 mice. However, when CpdA was administered to DBA/1 mice at a similar 
cumulative concentration via intraperitoneal injections every other day, CpdA was able to 
suppress inflammation as assessed by the disease activity score and measurement of paw 
thickness. This again confirms our hypothesis that the release of CpdA from the slow-release 
pellets is not constant over time, but rather results in an initial peak level of CpdA that may be 
toxic to DBA/1 mice. Nevertheless, when a constant administration of CpdA is guaranteed 
using intraperitoneal injections, it acts in an anti-inflammatory manner. These 
pharmacokinetic differences between subcutaneous and intraperitoneal application may 
affect both efficacy and side effects of this compound. In light of the observed toxicity of 
CpdA, we were unable to use higher concentrations of CpdA that might have been more 
potent in reducing inflammation [92]. The strain susceptibilities to the disease models and 
CpdA are summarized in Table 5. 
 
    Table 5. Susceptibility of mouse strains to disease models. 
Strain/disease model GIO Arthritis 
CpdA 
tolerance 
FVB/N Yes No Good 
DBA/1 No Yes Poor 
C57BL/6 Yes (mildly)* Yes (mildly) Poor 
    *in our experimental set-up not detectable 
 
In addition, two third of the arthritic mice treated with CpdA developed diarrhea suggesting 
that CpdA may only affect the gastrointestinal tract in combination with systemic 
inflammation. Enhanced colonic apoptosis, as evidenced by increased expression of pro-
apoptotic genes caspase-3 and caspase-7, may represent a potential underlying mechanism. 
These effects were not observed in healthy animals treated with the same dose of CpdA and 
may depend on an increased rate of apoptosis in the colonic tissue of CpdA-treated animals 
compared to GC- or vehicle-treated mice [92]. Reuter et al. reported similar side effects as 
they showed an increased apoptosis-rate in colonic tissue after CpdA treatment [100]. The 
observed pro-apoptotic effects of CpdA, however, seem to be CpdA-specific rather than 
SEGRA-specific, as a second tested SEGRA in that study, ZK216348, did not reveal 
apoptosis-inducing effects [100]. The fact that CpdA is an aziridine precursor which degrades 
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into aziridines at physiological pH could be again one possible explanation for the pro-
apoptotic effects of CpdA in vivo [79,109], because these alkylating reagents are highly 
reactive and may responsible for the toxic effects of CpdA at higher dosages [66,92,100]. It is 
conceivable that these adverse reactions are triggered or further intensified by free radicals 
and the inflammatory microenvironment in arthritis, at least partially explaining the 
gastrointestinal irritations in arthritic, but not healthy mice. If the experiment would be 
confirmed in humans, this would limit its therapeutic potential. 
 
5.4 Future prospects 
This study represents one of the first investigating the effects of the SEGRA CpdA on bone 
metabolism. In respect of the important role of the GR in several physiological responses and 
the ubiquitous occurrence in many different cells, tissues, and organs it will be indispensable 
to further progress in the development and characterization of SEGRAs according to their 
pharmacology and anti-inflammatory properties. Apart from showing the bone-sparing 
properties of CpdA, the presented work underlines the anti-inflammatory potential of this 
compound. Even though, CpdA works less anti-inflammatory compared to a conventional GC 
such as DEX, the idea of dissociating GR agonists seems to be promising and should be in 
the focus of further investigations. SEGRAs still have great potential in the treatment of 
inflammatory diseases and the optimization could further become a worthwhile therapeutic 
concept. The aim of following studies could be the development of new SEGRAs with a 
greater anti-inflammatory potential and broader therapeutic window.  
 
 Besides the well-studied RANKL/OPG system, another encouraging field for further 
investigations is the GC regulation of the Wnt signaling pathway. Our data show, that Dkk-1, 
an inhibitor of Wnt signaling, is increased after GC treatment, suggesting a possible starting 
point to investigate the mechanisms leading to GC-induced bone loss. Therefore future 
studies should address the impact of Dkk-1 in the pathogenesis of GIO. Possible strategies 
could include the characterization of cell-specific knock-out of Dkk-1 in osteoblasts or 
osteocytes regarding bone metabolism itself or in combination with GC treatment. To analyze 
the role of Dkk-1 in arthritis-induced bone loss, common arthritis models such as the 
collagen-induced arthritis model, used in the current study or the K/BxN model, could be used 
in these transgenic mice.  
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5.5 Concluding remarks  
Testing the hypothesis of this thesis, that the GR modulator CpdA suppresses inflammation 
while preventing skeletal side effects, required the use of two different mouse models. Our 
studies suggest that the tested SEGRA CpdA, has bone-sparing potential based on the 
preservation of bone formation while preventing bone resorption. Furthermore, CpdA exerts 
anti-inflammatory effects as indicated by lowering signs of inflammation, but failed to prevent 
arthritis-induced bone loss compared to conventional GC (Fig. 34). Additionally, by preventing 
increases in the RANKL/OPG ratio or Dkk-1, GC-induced bone loss may be ameliorated. In 
spite of the lower anti-inflammatory potential of CpdA, the concept of SEGRAs seems to have 
great potential and should be further progressed.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 34. Bone-sparing functions of compound A (CpdA). CpdA displays bone-sparing potential 
on several levels. It maintains the increase of the RANKL/OPG ratio, while preventing the inhibition of 
bone formation through activation of Wnt inhibitors such as dickkopf-1 (Dkk-1). Besides their bone-
sparing effects, CpdA is less anti-inflammatory compared to glucocorticoids (GC). In contrast, GC 
induce RANKL/OPG and therewith osteoclast differentiation, while inhibiting apoptosis of these cells. 
Moreover, apoptosis of osteoblasts is increased, whereas differentiation and function is increased. 
Besides, the potent anti-inflammatory effects of GC, they have adverse effects on the skeleton and 
induce bone loss leading to GC-induced osteoporosis (GIO). 
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6  Summary 
Rheumatoid arthritis (RA) is a common chronic inflammatory disease that affects about 1% of 
the Western population. Glucocorticoids (GC) are widely used for the treatment of RA and 
other immune-mediated diseases, such as asthma, but their use is associated with adverse 
effects on bone metabolism. Because of that, new selective GC receptor (GR) agonists 
(SEGRAs) with the potential for an improved risk/benefit profile have been developed. 
Compound A (CpdA) is a novel SEGRA, which showed an improved risk/benefit profile 
concerning glucose metabolism, however the effects on bone are not well investigated yet. 
Initial in vitro studies of our group showed bone-sparing potential of CpdA. The aim of this 
study was to investigate whether CpdA also possesses beneficial effects on bone in vivo. 
Therefore, the first step was to explore the effects of CpdA on healthy bone metabolism, 
followed by the analysis of the anti-inflammatory potential in a murine model of RA.  
 
To mimic the effects of continuous therapy, bone loss was induced in FVB/N mice by 
implanting slow-release pellets containing placebo, prednisolone (PRED; 3.5 mg), or CpdA 
(3.5 mg). After four weeks, mice were killed and the effects on the skeleton were examined. 
By performing in vitro studies with human bone marrow stromal cells (BMSC) and murine 
osteocyte-like cells (MLO-Y4 cells), the underlying mechanisms were assessed. Here, we 
focused on the RANKL/OPG ratio as a marker for the osteoclastogenic potential as well as on 
the Wnt signaling pathway. Whereas PRED reduced the total and trabecular bone density in 
the femur and in the spine, CpdA did not influence these parameters. These results were 
confirmed by histomorphometry as the mineral apposition rate was decreased by PRED 
whereas the number of osteoclasts was increased. Reduced bone formation was furthermore 
paralleled by a decline in the serum bone formation marker pro-collagen type 1 N-terminal 
peptide (P1NP) and decreased skeletal expression of osteoblast markers, as well as 
increased serum levels of the osteoblast inhibitor dickkopf-1 (Dkk-1). Additionally, serum 
CTX-1 and the RANKL/OPG ratio in the bone tissue were increased by PRED. None of these 
effects were observed with CpdA. Moreover, CpdA did not increase the RANKL/OPG ratio in 
MLO-Y4 cells and failed to transactivate Dkk-1 expression in bone tissue, BMSC, and 
osteocytes.  
 
To analyze the anti-inflammatory properties of CpdA, arthritis was induced in DBA/1 
mice by injection of type II collagen. After disease onset, mice were treated for ten days with 
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PBS (placebo), dexamethasone (DEX; 100 µg/mouse), or CpdA (300 µg/mouse). The latter 
was able to decrease disease activity, paw swelling, and paw temperature, but was less 
potent compared to DEX. In addition, T cells isolated from CpdA- and DEX-treated animals 
were less active based on proliferation rates after stimulation with type II collagen and 
produced smaller amounts of interferon-γ as compared to T cells from PBS-treated mice. The 
weaker potency of CpdA as compared to DEX in preventing infiltration of inflammatory cells, 
induction of osteoclastogenesis, and destruction of articular cartilage was confirmed by 
histological assessment of the joints. While CpdA was unable to prevent inflammation-
induced bone loss, it did not aggravate bone loss or alter bone density in healthy control 
mice. 
 
In conclusion, this study underlines the bone-sparing potential of CpdA compared to 
conventional GC in a murine model of GC-induced bone loss. Even though a moderate anti-
inflammatory potential of CpdA was demonstrated, it was unable to prevent inflammation-
induced bone loss. Despite the bone-sparing effects of CpdA in healthy mice, its narrow 
therapeutic window limits its use in clinical practice. Nevertheless, this study highlights 
important molecular mechanisms of GC-induced bone loss showing that by avoiding 
increases in the RANKL/OPG ratio or Dkk-1 in osteoblast lineage cells, GC-induced bone 
loss may be improved.  
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7  Zusammenfassung 
Rund 1% der westlichen Bevölkerung leidet an rheumatoider Arthritis, einer chronischen 
Entzündung der Gelenke. Für deren Behandlung werden häufig Glukokortikoide (GC) 
eingesetzt. Trotz ihrer potenten entzündungshemmenden Wirkung ist ihr Einsatz aufgrund 
der negativen Auswirkungen auf den Knochenstoffwechsel eingeschränkt. Um ein besseres 
Risiko/Nutzen-Profil zu erzielen, wurden selektive GC-Rezeptoragonisten (SEGRAs)  
entwickelt, die weiterhin potent anti-inflammatorisch wirken, während negative metabolische 
Effekte ausbleiben. Compound A (CpdA) ist ein Vertreter dieser Gruppe, der in Mäusen ein 
verbessertes Behandlungsprofil hinsichtlich des Glukosestoffwechsels zeigte. Die Wirkung 
auf den Knochen wurde bisher nur unzureichend untersucht. Erste in vitro Ergebnisse 
unserer Gruppe zeigten knochenfördernde Eigenschaften von CpdA. Ziel dieser Arbeit war es 
zu untersuchen, ob CpdA auch in vivo ein knochenschonendes Potenzial besitzt. Dafür 
wurden zunächst die Effekte von CpdA auf den gesunden Knochenstoffwechsel untersucht, 
um anschließend seine Wirkung in einem Mausmodell der rheumatoiden Arthritis zu testen. 
 
Um die Effekte einer Dauertherapie mit CpdA nachzustellen, wurden Slow-release-
Pellets mit Plazebo, Prednisolon (PRED; 3,5 mg) beziehungsweise CpdA (3,5 mg) in FVB/N-
Mäuse implantiert. Nach vier Wochen wurden die Effekte der Substanzen auf den Knochen 
untersucht. Um mögliche zugrundeliegende Mechanismen zu eruieren, wurden humane 
Knochenmarkszellen und murine Osteozyten-ähnliche Zellen (MLO-Y4-Zellen) genutzt. In 
diesen wurde der Einfluss der Substanzen auf das RANKL/OPG-Verhältnis, als einen Marker 
der Osteoklastenfunktion, sowie auf Dickkopf-1, einen Inhibitor des Wnt-Signalwegs, 
getestet. Während PRED die totale und trabekuläre Knochendichte im Femur und der 
Wirbelsäule verminderte, zeigte CpdA keinen Einfluss auf diese Parameter. Diese 
Ergebnisse wurden durch die histomorphometrische Analyse bestätigt und zeigten des 
Weiteren, dass PRED die Mineralanbaurate reduzierte während es die Anzahl der 
Osteoklasten erhöhte. Die verminderte Osteoblastenfunktion ging mit einer Abnahme der 
Knochenformationsmarker im Serum und im Knochengewebe einher.  Außerdem wurden der 
Resorptionsmarker im Serum und das RANKL/OPG-Verhältnis im Knochengewebe von 
PRED erhöht. Bei CpdA-behandelten Tieren wurden keine dieser Effekte beobachtet. Zudem 
wurde das RANKL/OPG-Verhältnis in vitro in MLO-Y4-Zellen durch CpdA nicht beeinflusst 
und auch die Transaktivierung von Dkk-1 im Knochengewebe, in Knochenmarkszellen und 
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Osteozyten blieb aus, was somit eine mögliche Erklärung für die knochenschonende Wirkung 
von CpdA darstellen könnte.  
 
Um die entzündungshemmenden Eigenschaften von CpdA zu untersuchen, wurde 
mittels einer Kollageninjektion Arthritis in DBA/1-Mäusen induziert. Nachdem die Mäuse eine 
Arthritis entwickelt hatten, wurden sie jeden zweiten Tag über eine Dauer von zehn Tagen mit 
PBS (Vehikel), Dexamethason (DEX; 100 µg/Maus) oder CpdA (300 µg/Maus) behandelt. 
CpdA war in der Lage die Krankheitsaktivität, die Pfotendicke und die Pfotentemperatur zu 
senken. Dabei war es aber nicht so effektiv wie DEX. Außerdem konnte gezeigt werden, dass 
T-Zellen, die aus CpdA- und DEX- behandelten Tieren isoliert und mit Kollagen stimuliert 
wurden, basierend auf ihrer Proliferationsrate weniger aktiv waren und geringere Mengen an 
Interferon-γ produzierten, als T-Zellen, die aus PBS-behandelten Tieren entnommen wurden. 
Das schwächere entzündungshemmende Potenzial von CpdA, verglichen mit DEX, wurde 
mittels der histologischen Analyse der Gelenke bestätigt. Es konnte eine höhere Infiltration 
von Entzündungszellen, sowie eine erhöhte Osteoklastogenese und Knorpelzerstörung in 
CpdA-behandelten Tieren beobachtet werden. Obwohl CpdA nicht in der Lage war, vor dem 
entzündungsbedingten Knochenverlust zu schützen, verschlimmerte es weder den 
Knochenverlust, noch veränderte es die Knochendichte in gesunden Kontrollmäusen. 
 
Diese Studie zeigt das knochenschonende Potenzial von CpdA in einem 
Mausmodell des GC-induzierten Knochenverlustes und bestätigt die moderaten 
entzündungshemmenden Eigenschaften von CpdA in vivo. Trotz der knochenschonenden 
Effekte von CpdA in gesunden Mäusen wird sein Einsatz in der klinischen Praxis durch die 
schmale therapeutische Breite erschwert. Trotz alledem deutet unsere Studie mit CpdA auf 
wichtige molekulare Mechanismen hin. Somit könnte durch das Verhindern der Erhöhung des 
RANKL/OPG-Quotienten oder von Dkk-1 in osteogenen Zellen, der durch GC verursachte 
Knochenverlust möglicherweise verhindert werden. 
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9 Abbreviations 
ACTH Adrenocorticotropic hormone 
ALP Alkaline phosphatase 
BFR Bone formation rate 
BMD Bone mineral density 
BMP Bone morphogenetic protein 
BMSC Bone marrow stromal cells 
BS Bone surface 
BS/BV Bone surface/bone volume 
BV/TV Bone volume/total volume 
CD3 Cluster of differentiation 3 
CII Collagen-type II 
CO Control, vehicle, non-arthritic 
CpdA Compound A 
CRH Corticotropin-releasing hormone 
CSMI Cross-sectional moment of inertia 
CT Threshold cycles 
CTX-1 C-terminal collagen type I crosslinks 
DEX Dexamethasone 
Dkk-1 Dickkopf-1 
FACS Fluorescence-activated cell sorting (flow cytometry) 
FZD Frizzled 
GAPDH Glyceraldehyde 3-phosphate dehydrogenase 
GC Glucocorticoid, glucocorticoids 
GIO Glucocorticoid-induced osteoporosis 
GR Glucocorticoid receptor 
GRE Glucocorticoid response elements 
HE Hemalum 
hMSC Human mesenchymal stromal cells 
IFN-γ Interferon-γ 
IgG Immunoglobuline G 
IL-6 Interleukin-6 
L4 Fourth vertebral body 
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LPS Lipopolysaccharide 
MAR Mineral apposition rate 
M-CSF Macrophage colony-stimulating factor 
MLO Murine long bone 
MSC Mesenchymal stem cells 
NFAT Nuclear factor of activated T-cells 
NF-κB Nuclear factor kappa-light-chain-enhancer of activated B cells 
NR3C1 Nuclear receptor subfamily 3, group C, member 1 (=glucocorticoid 
receptor) 
Oc.N Number of osteoclasts 
Oc.S/BS Osteoclast surface/bone surface 
OCN Osteocalcin 
OPG Osteoprotegerin 
OSCAR Osteoclast-associated receptor 
P1NP Pro-collagen type 1 N-terminal peptide 
PAGE Polyacrylamide gel electrophoresis 
PBMCs Peripheral blood mononuclear cells 
PBS Phosphat-buffered salt solution 
PCP Planar cell polarity 
PCR Polymerase chain reaction 
PE Phycoerythrin 
PFA Paraformaldehyd 
pQCT Peripheral quantitative computed tomography 
PRED Prednisolone 
RA Rheumatoid arthritis 
RANK(L) Receptor activator of nuclear factor-κB (Ligand) 
RU-486 Mifepristone 
RUNX2 Runt-related transcription factor 2 
Saos Derived from „Sarcoma osteogenic“ 
SDS Sodiumdodecylsulfate 
SEGRA Selective glucocorticoid receptor modulator 
SFRP1 Secreted frizzled-related protein 1 
Sost Sclerostin 
T.Ar Total area 
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Tb.Dn Trabecular density 
Tb.N Trabecular number 
Tb.Sp Trabecular separation 
Tb.Th Trabecular thickness 
TBS-T Tris-buffered saline with Tween 20 
TCF/ LEF T-cell-factor/lymphoid enhancer factor 
TNF Tumor necrosis factor 
TNFS11 TNF superfamily member 11 
TNF-α Tumor necrosis factor-α 
TRANCE TNF-related activation-induced cytokine 
TRAP Tartrate-resistant acid phosphatase 
Tt.Dn Total density 
WIF-1 Wnt-inhibitory factor 1 
Wnt Wingless-type MMTV integration site family 
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